Tapi[INVESTIGATOR_191750]-505-3003
Dermavant Sciences GmbH Clinical Study Protocol 
Confidential Page 1CLINICAL STUDY PROTOCOL
Title A Long-Term, Open-Label, Extension Study to Evaluate the S afety 
and Efficacy of Tapi[INVESTIGATOR_191751], 1% for the Treatment of Plaque 
Psoriasis in Adults
Sponsor Dermavant Sciences GmbH
Viaduktstrasse [ZIP_CODE] Basel, Switzerland
Compound Name [CONTACT_191867]-505 (tapi[INVESTIGATOR_191752])
Protocol Number DMVT-505-3003
Indication Plaque Psoriasis
Development Phase 3
IND Number 104601
Version/
Effective Date:Original Protocol                            30-JANUARY-2019
Amendment 1 (Version 1.0)          16-DEC-2019
DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 2  SPONSOR SIGNATURE [CONTACT_127942]:  A Long-Term, Open-Label, Extension Study to Evaluate the Safety and Efficacy of 
Tapi[INVESTIGATOR_191751], 1% for the Treatment of Plaque Psoriasis in Adults  
Protocol Number:  DMVT-505-3003 
 
This protocol has been approved by a representative of Dermavant Sciences, Inc. The following 
signature [CONTACT_139142]. 
 
   
   
 
 DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4

Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 3 MEDICAL MONITOR/SPONSOR INFORMATION PAGE 
Medical Monitor/serious adverse event (SAE) Contact [CONTACT_191820] [ADDRESS_227871]., Suite 240 
Durham, NC [ZIP_CODE] [LOCATION_003] 
 DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4

Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 4 INVESTIGATOR STATEMENT 
Study Title: A Long-Term, Open-Label, Extension Study to Evaluate the Safety and Efficacy of 
Tapi[INVESTIGATOR_191751], 1% for the Treatment of Plaque Psoriasis in Adults 
x I confirm agreement to conduct the study in compliance with the protocol. 
x I acknowledge that I am responsible for overall study conduct. I agree to personally conduct or supervise the described study. 
x I agree to ensure that all associates, coll eagues, and employees assisting in the 
conduct of the study are informed about their obligations and comply with the study protocol. Mechanisms are in place to ensure that site staff receives the appropriate 
information throughout the study. 
 
 
   
Principal Investigator [CONTACT_5627] (Printed)  Signature 
   
[CONTACT_191868]: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 5 TABLE OF CONTENTS 
ABBREVIATIONS ................................................................................................................. ......10  
SYNOPSIS  ..................................................................................................................... ...............12  
SCHEDULE OF ASS ESSMENTS ................................................................................................16  
1. INTRODUCTION ......................................................................................................19  
1.1. Background Information and Study Rationale ...........................................................19  
1.1.1.  Background Information .............................................................................................19  
1.1.2.  Study Rationale ...........................................................................................................21  
1.2. Rationale for Study Design and Dose .........................................................................21  
1.3. Potential Risks and Benefits .......................................................................................21  
1.3.1.  Risk Assessment .........................................................................................................21  
[IP_ADDRESS].  Dermatological Adverse Events, Including Skin Irritation or Allergic 
Reaction ...................................................................................................................... 21 
[IP_ADDRESS].  Systemic Adverse Events ...........................................................................................22  
[IP_ADDRESS].  Reproductive and Developmental Toxicity ................................................................22  
1.3.2.  Benefit Assessment .....................................................................................................23  
1.3.3.  Overall Benefit/Risk ...................................................................................................[ADDRESS_227872] to Follow-up .......................................................................................................30  DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 6 5. STUDY TREATMENT ..............................................................................................31  
5.1. Study Drug ..................................................................................................................31  
5.1.1.  Description, Packaging, and Labeling ........................................................................31  
5.1.2.  Storage ....................................................................................................................... .31 
5.1.3.  Handling and Disposal ................................................................................................31  
5.1.4.  Preparation ..................................................................................................................3 2 
5.1.5.  Administration of Study Drug ....................................................................................32  
[IP_ADDRESS].  Treatment by [CONTACT_191821] ....................................................32  
[IP_ADDRESS].  Disease Worsening (Physician Global Assessment Score ≥ 2) During the 
Study ......................................................................................................................... ..32 
[IP_ADDRESS].  Application of Study Drug ..........................................................................................33  
5.2. Randomization/Treatment Assignment ......................................................................34  
5.3. Blinding ......................................................................................................................34  
5.4. Compliance with Study Drug Administration ............................................................34  
5.5. Treatment after the End of the Study ..........................................................................34  
5.6. Prior and Concomitant Therapy ..................................................................................35  
5.6.1.  Permitted Medications and Nondrug Therapi[INVESTIGATOR_014] .........................................................35  
5.6.2.  Prohibited Medications and Nondrug Therapi[INVESTIGATOR_014] ........................................................35  
6. STUDY ASSESSMENTS AND PROCEDURES ......................................................36  
6.1. Medical History and Demography..............................................................................36  
6.1.1.  Medical History ..........................................................................................................36  
6.1.2.  Demographics .............................................................................................................36  
6.2. Efficacy Assessments .................................................................................................36  
6.2.1.  Assessments by [CONTACT_10670] .......................................................................................36  
[IP_ADDRESS].  Physician Global Assessment .....................................................................................36  
[IP_ADDRESS].  Body Surface Area ......................................................................................................37  
[IP_ADDRESS].  Psoriasis Area and Severity Index ..............................................................................[ADDRESS_227873] ...........................................................................37  
[IP_ADDRESS].  Dermatology Life-Quality Index ................................................................................37  
[IP_ADDRESS].  Patient Satisfaction Questionnaire ..............................................................................37  
6.2.3.  Optional Clinical Photography ...................................................................................37  
6.3. Safety Assessments .....................................................................................................38  DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 7 6.3.1.  Adverse Events ...........................................................................................................38  
6.3.2.  Brief Physical Examination ........................................................................................38  
6.3.3.  Vital Signs ..................................................................................................................3 8 
6.3.4.  Clinical Safety Laboratory Assessments ....................................................................38  
6.3.5.  Local Tolerability Scale ..............................................................................................40  
6.4. Treatment of Study Drug Overdose ............................................................................40  
6.5. Pharmacokinetics/Pharmacodynamics .......................................................................40  
7. TIMING OF PROCEDURES AND ASSESSMENTS ..............................................41  
7.1. Visit 1; Baseline ..........................................................................................................41  
7.2. Visits 2 to 10; Treatment Period .................................................................................42  
7.3. Visit 11; ......................................................................................................................[ADDRESS_227874] at Week 2 (Day 15 ±3 Days) ..............................................................[ADDRESS_227875] .............................................................................48  
8.2. Classification of Adverse Events ................................................................................48  
8.2.1.  Assigning Severity Rating for Adverse Events ..........................................................48  
[IP_ADDRESS].  Criteria for Determining Adverse Event Severity ......................................................48  
[IP_ADDRESS].  Toxicity Management Criteria ....................................................................................49  
8.2.2.  Assigning Causal Relationship to Study Drug ...........................................................50  
8.3. Time Period and Frequency for Event Assessment and Follow-up ...........................50  
8.3.1.  Adverse Event Reporting ............................................................................................50  
8.3.2.  Follow-up of Adverse Events .....................................................................................51  
8.4. Reporting Procedures ..................................................................................................51  
8.4.1.  Serious Adverse Event Reporting ...............................................................................51  DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-[ADDRESS_227876]/Independent Ethics Committee Approval ......................57  
11.1.3.  Informed Consent/Assent ...........................................................................................57  
11.1.4.  Confidentiality ............................................................................................................58  
11.1.5.  Study Files and Retention of Records ........................................................................58  
11.1.6.  Electronic Case Report Forms ....................................................................................59  
11.1.7.  Drug Accountability ...................................................................................................59  
11.1.8.  Inspections ..................................................................................................................6 0 
11.1.9.  Protocol Compliance ..................................................................................................60  
11.2.  Sponsor Responsibilities .............................................................................................60  
11.2.1.  Protocol Modifications ...............................................................................................60  
11.2.2.  Study Report and Publications....................................................................................60  
11.2.3.  Posting of Information on Publicly Available Clinical Trial Registers ......................61  
11.3.  Joint Investigator/Sponsor Responsibilities ................................................................61  DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003
Dermavant Sciences GmbH Clinical Study Protocol 
Confidential Page 911.3.1. Access to Information for Monitoring........................................................................61
11.3.2. Access to Information for Auditing or Inspections ....................................................6111.3.3. Study Discontinuation ................................................................................................6112. REFERENCES ...........................................................................................................6213. APPENDICES ............................................................................................................63
Physician Global Assessment................................................................................63
Calculation of Percent Body Surf ace Area (%BSA) Affected and 
Psoriasis Area Severity Index (PASI).........................................................................64
Dermatology Life Quality Index (DLQI) Ages [ADDRESS_227877] OF TABLES
Table 1: Schedule of  Assessments............................................................................................16
Table 2 Tapi[INVESTIGATOR_191751].........................................................................................................3 1
Table 3: Laboratory Tests .........................................................................................................39
Table 4: Criteria for Determining the Grade/Severity of Adverse Event Terms Not 
Specified by [CONTACT_191822] ...................................................49DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-[ADDRESS_227878] DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-[ADDRESS_227879] deviation 
TAMA therapeutic AhR-modulating agent 
TEAE treatment-emergent adverse event 
UNSCH unscheduled 
US; [LOCATION_003] [LOCATION_002] (of America) 
UV ultraviolet 
WBC white blood cells 
WHO World Health Organization  DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 12 SYNOPSIS 
Name [CONTACT_790]/Company:  
Dermavant Sciences GmbH 
Name [CONTACT_791]:  
DMVT-505 (tapi[INVESTIGATOR_191753], 1%) 
Name [CONTACT_3261]:  
Tapi[INVESTIGATOR_191754]: DVT-505-3003 Phase: 3 Country:  US and Canada 
Title of Study:  
A Long-Term, Open-Label, Extension Study to Evaluate the Safety and Efficacy of Tapi[INVESTIGATOR_191751], 1% for the 
Treatment of Plaque Psoriasis in Adults 
Study Centers:  
Approximately 100 to 120 sites in the [LOCATION_002] (US) and Canada  
Objectives: 
x To evaluate the safety and tolerability of tapi[INVESTIGATOR_191755], 1% in adults with plaque psoriasis  
x To describe the efficacy of tapi[INVESTIGATOR_191753], 1% over an extended period of time in adults with plaque 
psoriasis 
x To describe the effect of tapi[INVESTIGATOR_191753], 1% on psoriasis symptom severity  and the associated impact on 
daily activities and attitudes in ad ults with plaque psoriasis  
Methodology:  
This is a long-term, open-label, multicenter, study to ev aluate the safety and efficacy of topi[INVESTIGATOR_191756],  1% in adults with plaque psoriasis.  Subjects in this study completed treatment with tapi[INVESTIGATOR_191757] 1 of 2 
Phase  3 pi[INVESTIGATOR_191758] (Study DMVT-505-3001 or Study DMVT-505-3002).  This study will 
consist of up to 40 weeks of treatment and a 4-week safety follow-up period. 
At the completion of the Week -12 visit of the pi[INVESTIGATOR_2397] (Baseline [Day 1] in this study), all eligible subje cts 
will be offered enrollment in the long -term extension study.  Study visits during the treatment period for all 
subjects will occur every 4  weeks (± 3 days).  Unscheduled visits may occur, as needed.  Subjects who withdraw 
from the study before Week  40 will return to the study center for an Early Termination visit.  The total duration of 
study participation will be approximately 4 4 weeks. 
Subjects in the study will be treated based on their PGA score from the Week 12 visit in the pi[INVESTIGATOR_2397]. Subjects 
entering with a PGA  ≥ 1 will receive treatment with tapi[INVESTIGATOR_191753], 1% until they achieve a PGA score of 0, at 
which time treatment will be discontinued an d subjects monitored for durability of response.  If disease worsening 
occurs, as evidenced by a PGA ≥ 2, treatment will then be re -initiated and continued until a PGA of [ADDRESS_227880] treatment discontinued and be monitored for dura bility of response. If 
disease worsening occurs, as evidenced by a PGA ≥ 2, then treatment will be re- initiated and continued until a 
PGA of 0 is observed.   This treatment and re- treatment pattern of use will be continued until the end of the study 
(i.e., subjects may receive study treatment up until the Week 40 visit).  
Study drug w ill be dispensed to subjects during the study visits and will be administered at home between study 
visits as instructed by [CONTACT_8786].  Subjects will be instructed to appl y study drug once daily to all affected 
areas, including newly appearing lesions  and lesions or affected areas that improve during the study.  Subjects will 
apply sufficient study drug to cover completely each lesion with a thin layer of study drug and will record the time 
of study drug application in a daily diary provided by [CONTACT_191823].  (Note that subjects are allowed, but not 
required, to treat fingernails, toenails, palms, soles and scalp lesions with study drug; however, efficacy analyses 
will not include assessment of improvement of psoriasis in these areas ).  Subjects will be instructed to maintain the 
approximate dosing time chosen at the beginning of the study for their full study participation.  Study drug 
application instructions will be reviewed at subsequent study visits.  During subsequent study visits, subjects will DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-[ADDRESS_227881] been completed , if applicable.  The time of the study drug application and assessments 
will depend on the time of the study visit (either morning or afternoon visit).  Therefore, the timing of the study 
visit may lead to a change from the subject’s chosen dosing time; if this occurs, it will NOT be considered a 
protocol deviation; the subject should resume their chosen do sing time the day following any such study visit 
study drug  application. This should only occur for subjects receiving study treatment.   
Rescue medications may be initiated with consultation of the medical monitor. 
Sample Size Justification: 
The sample size of this study is based on the Internatio nal Conference on Harmonisation (ICH) E1 guideline on 
extent of population exposure to assess clinical safe ty for drugs intended for long-term treatment of 
non-life-threatening conditions.  An estimated 850 subjects who complete Study DMVT-505-3001 or 
Study  DMVT-505-3002 will be enrolled in this study across all regions.  A high discontinuation rate is 
anticipated in this long -term extension study.  Approximately 300 subjects are expected to complete the study 
(up to 40 weeks of treatment). 
Number of Subjects (planned):  
Approximately 850 subjects ages 18 to 75 years of age 
Diagnosis and Main Criteria for Inclusion:  
Inclusion criteria: 
1. Completed the 12-week treatment period in 1 of the 2 pi[INVESTIGATOR_36491] (Study DMVT-505-3001 or 
Study DMVT-505-3002); 
2. Male or female; 
3. Female subjects of childbearing potential and male su bjects who are engaging in sexual activity that 
could lead to pregnancy should use one of the following acceptable birth control met hods while on study 
and for [ADDRESS_227882] exposure to study drug.  Acceptable contraception methods are: 
x Female subject or male subject’s female partner is surgically sterile (b ilateral tubal ligation, 
hysterectomy, bilateral oophorectomy) for a m inimum of [ADDRESS_227883]’s female partner has had an intrauterine device in place for at least [ADDRESS_227884] dose of study drug 
x Double barrier methods (e.g., condom plus diaphr agm, condom or diaphragm plus spermicide) 
starting at least [ADDRESS_227885] dose of study drug 
x Subjects who claim abstinence as their method of contraception are allowed provided they agree to 
use a double barrier method (e.g., condom plus diaphrag m, condom or diaphragm plus spermicide) 
should they become sexually active from Screening to [ADDRESS_227886]’s male partner (vasectomy) a minimum of [ADDRESS_227887]’s female partner is taking hormonal contraceptives starting at least [ADDRESS_227888] agree to use a double barrier method (e.g., 
condom plus diaphragm, condom or diaphragm plus spermicide) from Screening through [ADDRESS_227889] label.  The Investig ator is responsible for ensuring that subjects 
understand how to properly use these methods of contraception. Non-CBP is defined as premenarchal 
or premenop ausal females with a documented bilateral tu bal ligation, bilateral oophorectomy (removal 
of the ovaries) or hysterectomy, or hysteroscop ic sterilization; or postmenopausal females defined as a 
cessation of menses for at least 12 months without an alternative medical cause.  In questionable cases 
a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 ml/U is confirmatory.   
Documented verbal history from the subject is acceptable.   DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 15 x Change and percent change from baseline in %BSA affected by [CONTACT_765] (OC and LOCF) 
x Change and percent change in PASI score by [CONTACT_765] (OC and LOCF) 
x Change in disease impact on daily activities, as me asured by [CONTACT_191824]: 
All study data will be summarized overall and by [CONTACT_191825][INVESTIGATOR_191759] -to-treat (ITT) analysis  set of subjects.  Categorical variables will be reported using frequency and 
percentage (e .g., sex, race).  Continuous variables will be reported using number of subjects, mean, standard 
deviation (SD) , median, minimum, and maximum.  All safety and efficacy data will be listed by [CONTACT_1130]. 
Demographics, baseline characteristics, and all safety asse ssments (including LTS assessments), will be analyzed 
using descriptiv e statistics.  The Kaplan-Meier product limit method will be used to estimate the median time 
(if estimable) from baseline to first diseas e worsening and first treatment success.  If the median is not estimable 
(e.g., < 50% of subjects worsen), other metho ds for estimating the median and/ or other percentiles of worsening 
will be applied.  All other efficacy assessment s will be analyzed using descriptive statistics. DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 16 SCHEDULE OF ASSESSMENTS 
Table 1: Schedule of Assessments 
 
Visit 1 Long-term Extension Period 
Procedures and 
Assessment Phone 
Call Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 7 Visit 8 Visit 9 Visit 10 Visit 11 Visit 12 Other Visits 
Base- 
linea 
Day 1 Week 2 
Day  
15 Week 4 
Day 
29 Week 8 
Day 
57 Week 12 
Day 
85 Week 16 
Day 
113 Week 20 
Day 
141 Week 24 
Day 
169 Week 28 
Day 
197 Week 32 
Day 
225 Week 36 
Day 
253 Week 40 
Day 
281 Week 44 
(F-U) 
Day 
309 
UNSCHb ETc ±3 
Days ±3 
Days ±3 
Days ±3 
Days ±3 
Days ±3 
Days ±3 
Days ±3 
Days ±3 
Days ±3 
Days ±3 
Days ±3 
Days 
Informed consent X               
Confirm eligibility X               
Demographics/ 
Medical History Xd               
Brief physical 
examination [X]  X X X X X X X X X X X X X 
Vital signs 
(pulse, BP, temperature)e [X]  X X X X X X X X X X X X X 
Urine pregnancy test 
(all females of CBP) [X]  X X X X X X X X X X X As 
needed X 
Clinical laboratory testsf [X]  X  X       X X As 
needed X 
Urinalysis X           X X As 
needed X 
Photography, if 
applicableg [X]  X X X X X X X X X X X X X 
Investigator assessed:e 
PGA [X]  
X X X X X X X X X X X X X 
BSA affectedh [X]  X X X X X X X X X X X X X 
PASI [X]  X X X X X X X X X X X X X 
LTSi   X X X X X X X X X X  X X DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 17  
Visit 1 Long-term Extension Period 
Procedures and 
Assessment Phone 
Call Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 7 Visit 8 Visit 9 Visit 10 Visit 11 Visit 12 Other Visits 
Base- 
linea 
Day 1 Week 2 
Day  
15 Week 4 
Day 
29 Week 8 
Day 
57 Week 12 
Day 
85 Week 16 
Day 
113 Week 20 
Day 
141 Week 24 
Day 
169 Week 28 
Day 
197 Week 32 
Day 
225 Week 36 
Day 
253 Week 40 
Day 
281 Week 44 
(F-U) 
Day 
309 
UNSCHb ETc ±3 
Days ±3 
Days ±3 
Days ±3 
Days ±3 
Days ±3 
Days ±3 
Days ±3 
Days ±3 
Days ±3 
Days ±3 
Days ±[ADDRESS_227890]:e 
DLQI [X]  
X X X X X X X X X X X  X 
LTSi   X X X X X X X X X X  X X 
Patient Satisfaction 
Questionnaire            X   X 
Adverse events X X X X X X X X X X X X X X X 
Concomitant medication X X X X X X X X X X X X X X X 
Dispense/collect diaryj X  X X X X X X X X X X  X X 
Review diaries for 
treatment compliance   X X X X X X X X X X  X X 
Dispense/collect 
study drugk D  C/D C/D C/D C/D C/D C/D C/D C/D C/D C  As 
needed C 
Review instructions for 
study drug applicationl X X X X X X X X X X X   As 
needed  
Study drug application 
under supervisionm X  X X X X X X X X X   X  
BP = blood pressure; BSA = body surface area; C = collect; CBP = child-bearing potential; D = disp ense; DLQI = Dermatology Life  Quality Index; ET = early 
termination; F-U = follow-up; LTS = Local Tolerability Scale; PASI = Psoriasis Area and Severity Index; PGA = Physician Global Assessment; 
UNSCH = unscheduled. 
a Visit to occur at the time of completion of Visit 6 (Week 12) in  pi[INVESTIGATOR_2397]. The last assessment completed as part of the p ivotal study will be used as the 
baseline value for assessments with a bracketed “X.”  
b Subjects who experience disease worsening (PGA ≥ 2) between scheduled study visits may contact [CONTACT_191826] (see 
Section [IP_ADDRESS] ). If disease worsening is confirmed, a new treatment course will be initiated. 
c Subjects who withdraw from the study before Week 40 will complete an ET visit. 
d As collected at Screening/Baseline in pi[INVESTIGATOR_2397]. DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 18 e Performed prior to study drug application on study visit days. 
f Serum chemistry (including liver chemistry tests) and hematology. 
g Photography will be performed in a subgroup of subjects at selec ted (approximately 20) study centers; this is not required of subjects for participation in the 
study. Informed consent and photographic release will be required. 
h %BSA affected must be performed before PASI. (Note that subj ects are allowed, but not required , to treat fingernails, toenails , palms, soles, and scalp lesions 
with study drug; however, efficacy analyses will not includ e assessment of improvement of psoriasis in these areas 
i The LTS assessment is only required to be completed if the subj ect was applying study drug for the period before the current v isit. 
j Study diary should only be dispensed if study product is dispensed. 
k Subjects will be monitored for disease worsening (PGA ≥ 2), and study drug administration may be star ted at any time during the observation period  (see 
Section [IP_ADDRESS] ) 
l Subjects will be instructed to apply study drug once daily at th e approximate same time each day, based on subject preference.  This should only occur for 
subjects receiving study treatment. 
m Study drug will be applied after safety assessments have been  conducted, . Subjects will be instructed and reminded on how to apply study drug at each visit, 
except during the final treatment visit (see Section [IP_ADDRESS]  for additional details on timing of study drug app lication during study visits). This should only occur 
for subjects receiving study treatment. 
 DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 19 1. INTRODUCTION 
1.1. Background Information and Study Rationale 
1.1.1. Background Information 
Psoriasis is a common, chronic relapsing inflammatory skin disease [ Parisi, 2012 ] with recurrent 
epi[INVESTIGATOR_191760] (plaques). Approximately 2% to 3% of 
the global population is affected by [CONTACT_22803]; those affected are predominantly adults, who are most often diagnosed between the ages of 18 to 35 years. Psoriasis disrupts daily activities such 
as work and/or school attendance, interpersona l relationships, recreational activities, and 
intimacy – thereby [CONTACT_191827]’ quality of life . Furthermore, psoriasis 
sufferers can also have co-morbidities such as arthritis, depression, inflammatory bowel disease, 
and cardiovascular diseases. 
Up to 80% of patients have mild to moderate plaque-type psoriasis, which is generally managed 
with topi[INVESTIGATOR_12969]. The most commonly used  treatments for psoriasis include topi[INVESTIGATOR_191761] D analogs, alone or in combination. Vitamin D analogs are 
moderately efficacious as monotherapy, while application of topi[INVESTIGATOR_11930] – particularly 
the very potent ones – is restricted in terms of body areas that can be treated and the duration of 
use due to the well-known application site and systemic adverse drug reactions [ Mason, 2013 ]. 
Although numerous topi[INVESTIGATOR_191762], there remains a need for a topi[INVESTIGATOR_191763] a high level of efficacy with an acceptable safety profile that permits application to a large body surface area (BSA) without restrictions on duration of treatment. 
DMVT-505 (tapi[INVESTIGATOR_191752]), formerly known as [COMPANY_004]2894512, is a fully synthetic hydroxylated stilbene that is being developed by [CONTACT_191828] (Dermavant) as a novel 
anti-inflammatory agent for the topi[INVESTIGATOR_22787] (AD) and plaque psoriasis. 
The compound (number WBI-1001) was initially developed by [CONTACT_191829]. (Welichem; Burnaby, British Columbia, Canada ) and then was acquired by [CONTACT_35316] 
([COMPANY_004]) on [ADDRESS_227891] of the world except China. Beijing Wenfeng Tianji Pharmaceuticals (BWTP) is developi[INVESTIGATOR_007] a compound in China identified as Benvitimod (active ingredient corresponds to tapi[INVESTIGATOR_191752]) with a unique topi[INVESTIGATOR_59420]. Dermavant acquired the drug from [COMPANY_004] on [ADDRESS_227892] 2018 for continued development. 
Tapi[INVESTIGATOR_191753], 1% is a white to off-white,  oil-in-water emulsion intended for topi[INVESTIGATOR_191764], which has a novel mechanism of action. The drug 
likely mediates its effects via the aryl hydrocarbon receptor (AhR) agonist and nuclear 
factor-erythroid 2-related factor-2 (Nrf2) because the pattern of pro-inflammatory mediators 
inhibited by [CONTACT_66597][INVESTIGATOR_191765], calcineurin inhibitors, vitamin D 
analogs, and other immunosuppressive agents commonly used to treat AD and psoriasis. Rather, the profile of biological responses elicited by [CONTACT_66597][INVESTIGATOR_191766], a common nonpr escription treatment for psoriasis. Together, 
existing data identify tapi[INVESTIGATOR_191767] a non-ster oid, therapeutic AhR-modulating agent (TAMA), 
which is a unique mechanism of action compared with existing therapi[INVESTIGATOR_014]. DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 20 Tapi[INVESTIGATOR_191768] l studies at concentrations up to 8% and in 
clinical studies at concentrations up to 2%. Three Phase I clinical pharmacology studies in 
healthy volunteers and 7 Phase I/II studies in subjects with AD and psoriasis have been 
completed. Refer to the current version of the tapi[INVESTIGATOR_191769]’s Brochure for detailed 
information. Tapi[INVESTIGATOR_191770] a clear therapeutic 
effect, as compared to vehicle, in both psoriasis and AD. 
Four randomized, double-blind, vehicle-controlled, cl inical studies to evaluate the safety and 
efficacy of topi[INVESTIGATOR_897]-applied tapi[INVESTIGATOR_191771]; one 28-day and one 12-week stud y was completed for each indication. 
These studies enrolled a total of 282 adult subjects,  with 235 subjects exposed to tapi[INVESTIGATOR_191753] 
0.5%, 1%, or 2% (Formulation C) once or twice daily for a period of [ADDRESS_227893] frequently reported (1 to 6% of 
235 subjects) dermatological adverse events (AEs),  regardless of causality, were application site 
discoloration/hyperpi[INVESTIGATOR_371], application site dermatitis, papular rash, pruritus, dermatitis 
contact, folliculitis, erythema, and skin burning  sensation. Nasopharyngitis and headache were 
the most frequently-reported (>10% of subjects) nondermatological AEs overall. Overall, results 
of the clinical studies indicated tapi[INVESTIGATOR_191772], with 
a favorable safety profile. 
The first clinical study with Formulation F (Study 201851) was a Phase 1 study to evaluate 
the systemic exposure and pharmacokinetic (PK) pa rameters of tapi[INVESTIGATOR_191753], 1% and 2%. 
This study was conducted in 11 subjects with AD; 5 subjects were treated with the 2% dose and 6 subjects were treated with the 1% dose. Head ache was the most frequently reported (100% and 
60% of subjects at the 1% and 2% doses, resp ectively) nondermatological adverse event. 
Two Phase 2b, 12-week, randomized, double-blind, vehicle-controlled, 6-arm, parallel-group, 
dose-finding studies with topi[INVESTIGATOR_191773]; 1 study each in subjects with AD or psoriasis. These 2 studies evaluated the safety and efficacy of 
tapi[INVESTIGATOR_191753] (Formulation F) at 2 concentrations (0.5% or 1%) and 2 application frequencies (once daily or twice daily) in [ADDRESS_227894] compared with vehicle, with the 
1% concentration treatment groups demonstrating a higher proportion of subjects with treatment success compared with the 0.5% concentration groups (applied once daily and twice daily in the 
AD study). In both indications, the tapi[INVESTIGATOR_191752] 1% dosing groups showed a faster onset of action 
than the 0.5% dosing groups, and once daily application had similar efficacy to twice daily 
application. In both Phase 2b studies, tapi[INVESTIGATOR_191774]. Treatment-
emergent adverse events (TEAEs) were reported w ith a higher frequency in the tapi[INVESTIGATOR_191775]. The most frequent TEAEs ( ≥5% in any arm or in total) were 
nasopharyngitis, folliculitis, dermatitis con tact, atopic dermatitis, upper respi[INVESTIGATOR_4348], headache, vomiting, acne,  application site dermatitis, miliaria, dermatitis allergic, and 
impetigo. The majority of TEAEs were mild or moderate in severity. In each study, the 
tapi[INVESTIGATOR_191752] 1% once daily treatment group had a lowe r frequency of TEAEs than the tapi[INVESTIGATOR_191752] 1% 
twice daily treatment group. DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 21 1.1.2. Study Rationale 
This 40-week, Phase 3, open-label extension stud y is being conducted as part of a clinical 
development program to evaluate the long-term safe ty and continued efficacy of tapi[INVESTIGATOR_191753], 
1% for the topi[INVESTIGATOR_191776].  Subjects in this study 
will be selected from those subjects who comp lete 1 of 2 Phase 3 pi[INVESTIGATOR_191777] (pi[INVESTIGATOR_191778]-505-3001 or pi [INVESTIGATOR_191778]-505-3002) and meet the 
predefined criteria to enroll into this study. 
1.2. Rationale for Study Design and Dose 
As in the pi[INVESTIGATOR_36491], this Phase [ADDRESS_227895] udy, is expected to be an adequate duration to 
assess safety and efficacy of repeated treatmen t courses of tapi[INVESTIGATOR_191779] E1 (ICH E1) guideline on the extent of population exposure to assess clinical safety for drugs intended for long-term treatment of non-life-
threatening conditions [ ICH, 1994 ], which recommends a minimum of [ADDRESS_227896] 1 year. 
The once daily topi[INVESTIGATOR_191780], 1% concentration administered in the 
pi[INVESTIGATOR_191781]-label extension study. 
1.3. Potential Risks and Benefits 
To assess any potential impact on subject eligibility with regard to safety, the Investigator must 
refer to the current ve rsion of the tapi[INVESTIGATOR_191769]’s Brochure for detailed information 
regarding warnings, precautions, contraindications, AEs, and other significant data pertaining to 
the study drug being used in this study. 
1.3.1. Risk Assessment 
[IP_ADDRESS]. Dermatological Adverse Events, Including Skin Irritation or Allergic Reaction 
Tapi[INVESTIGATOR_191782]. Allergic or irritant reactions in the exposed 
areas may present as erythema, edema, papules, or vesicles. In the event of pronounced skin 
reaction, spreading of the eczematous reaction beyond the original application site(s) and/or 
more generalized (remote) skin reactions may be observed. 
In the dose-ranging study [ADDRESS_227897] 
frequently reported dermatologic AEs were folliculitis and AD. Nonclinical dermal toxicity studies of up to 8% tapi[INVESTIGATOR_191783] 13 weeks indicated local effects are primarily mild to 
moderate skin irritation that is reversible; tapi[INVESTIGATOR_191784]. In 
initial clinical studies using a different formulation of tapi[INVESTIGATOR_191752] (Formulation C), AEs of skin DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-[ADDRESS_227898] s’ skin will be evaluated routinely for 
signs of irritation or allergic reaction, and if needed, study treatment will be interrupted and an 
appropriate treatment provided. Note that after cessation of exposure, dermatological reactions 
generally subside spontaneously or with topi[INVESTIGATOR_12969]. 
[IP_ADDRESS]. Systemic Adverse Events 
Nasopharyngitis and headache were the most frequently reported nondermatological AEs in 
dose-ranging Study [ADDRESS_227899] 
infection, and headache. In the initial clinical studies (in AD and psoriasis) using a different 
tapi[INVESTIGATOR_191785] (Formulation C), nasopharyng itis and headache were the most frequently 
reported nondermatological AEs. In the open-label PK Study 201851 with BID dosing of 
Formulation F of tapi[INVESTIGATOR_191753] (n=11), 1% an d 2%, headache was the most frequently 
reported AE during the study (reported for 100% and 60% of subjects at the 1% and 2% doses, respectively). 
In a nonclinical study in minipi[INVESTIGATOR_191786] (IV) administration, reversible decreases in 
arterial blood pressure and PR inte rval were observed; however, in this study and repeat dermal 
toxicity studies, there were no effects on QT interval or heart rate. Repeat-dose dermal toxicity 
studies also showed findings related to the liver (increased weights and hepatocellular hypertrophy/regeneration) and thym us (thymic cortex depletion in adult rabbits and rats; changes 
in thymus weight, microscopic decreased cellular ity, and changes in thymic T cell maturation in 
juvenile rats) with associated secondary hematological findings. Thymic findings were also noted in repeat adult and juvenile rat studies; however, there were no clinically relevant AEs/SAEs reported. 
To mitigate potential systemic risks, subjects w ill be monitored for AEs and any abnormal vital 
signs, physical examination, and laboratory test results. 
[IP_ADDRESS]. Reproductive and De velopmental Toxicity 
Results of embryo-fetal development studies in rats and rabbits indicated an increased risk for 
embryo-fetal developmental effects, as evidenced by [CONTACT_191830]-implantation loss and incidence of fetal skeletal variations. Results of a juvenile rat study indicated adverse 
microscopic changes in the form of renal pelvic dilatation in both sexes, along with reversible 
increases in total urinary glucose and protein excretion in males at ≥ 10/15 mg/kg/day tapi[INVESTIGATOR_191752] 
(administered subcutaneously). 
An investigative study in rats suggested an increased risk for hydronephrosis during a narrow 
window of postnatal sensitivity prior to postnatal day (PND) 32 (specifically PND 15 to 21). Rat renal tubule anatomic maturation and nephrogenesis occurs during this period [ Cappon, 2010;  
Frazier, 2013; Zoetis, 2003 ], however tubule morphogenesis/nephrogenesis occurs entirely 
prenatally in humans [ Cappon, 2010 ; Zoetis, 2003 ]. DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 23 To mitigate these potential risks, women of childbearing potential (CBP)must utilize abstinence 
or a highly effective method of contraception consistently and correctly during the study and for 4 weeks after the end of treatment (Section 4.2). Monthly pregnancy testing will be conducted. 
Pregnant women and subjects under 18 years of age will be excluded from the study. If a woman 
becomes pregnant during the study, she will  immediately discontinue study treatment. 
Additionally, AEs will be monitored and clinical laboratory testing will be performed. 
1.3.2. Benefit Assessment 
Subjects may experience improvements in their psoriasis during the course of the study and may 
benefit from the additional safety assessments conducted as part of the study (e.g., physical examination, laboratory tests). Subjects in the study will also contribute to the process of developi[INVESTIGATOR_007] a novel anti-inflammatory agent for the topi[INVESTIGATOR_179802]. 
1.3.3. Overall Benefit/Risk 
Taking into account the measures taken to minimize risk to subjects in this study, the potential 
risks identified in association with tapi[INVESTIGATOR_191787]. DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 25 3. STUDY DESIGN 
3.1. Overall Design 
This is a long-term, open-label, multicenter, study to evaluate the safety and efficacy of topi[INVESTIGATOR_191788], 1% in adults with plaque psori asis. Subjects in this study completed treatment 
with tapi[INVESTIGATOR_191789] 1 of 2 pi[INVESTIGATOR_191790] 3 pi[INVESTIGATOR_191758] 
(Study DMVT-505-3001 or Study DMVT-505-3002). The study will consist of up to 40 weeks 
of treatment and a 4-week safety follow-up period. 
At the completion of the Week-12 Visit of the pi[INVESTIGATOR_191791] (Baseline [Day 1] in this study), 
eligibility of the subjects opting to enroll in this  extension study will be confirmed. Study visits 
during the treatment period for all subjects will  occur every 4 weeks (±3 days). A Phone Call 
will be performed at Week 2 (Day 15).  Unscheduled visits may occur, as needed.  Subjects who 
withdraw from the study before Week 40 will return to the study center for an Early Termination 
Visit. The total duration of study participation will be approximately 44 weeks. 
Subjects in the study will be treated as follows based on their PGA score from the Week 12 visit 
in the pi[INVESTIGATOR_2397] (DMVT-505-3001 or DMVT-505-3002). 
x Subjects entering with a PGA ≥ 1 will receive treatment with tapi[INVESTIGATOR_191753], 1% 
until they achieve a PGA score of 0, at wh ich time treatment will be discontinued and 
subjects monitored for durability of response. If/when disease worsening occurs, as evidenced by a PGA ≥ 2, treatment will then be re-initiated and continued until a 
PGA of [ADDRESS_227900]  treatment discontinue d and be monitored 
for durability of response. If/when disease worsening occurs, as evidenced by a PGA ≥ 2, treatment will then be re-initiated and continued until a PGA of 0 is observed.    
x This treatment and re-treatment pattern of us e will be continued until the end of the 
study (ie, subjects may receive study treatment up until the Week 40 visit) (see Section [IP_ADDRESS] ). 
Study drug will be dispensed, and subjects will be instructed on how to apply study drug. Subjects will apply the daily dose of study drug while at the site, under the supervision of site personnel, after efficacy and safety assessments have been completed. 
Study drug will be dispensed to subjects during th e study visits and will be administered at home 
between study visits as instructed by [CONTACT_191831] l. Subjects will be instructed to apply study 
drug once daily to all affected areas, including newly appearing lesions and lesions or affected 
areas that improve during the study. Subjects will apply sufficient study drug to cover 
completely each lesion with a thin layer of study drug and will record the time of study drug 
application in a daily diary provided by [CONTACT_43038] y site. (Note that subjects are allowed, but not 
required, to treat fingernails, toenails, palms, so les, and scalp lesions with study drug; however, 
efficacy analyses will not include assessment of improvement of psoriasis in these areas.) Subjects will be instructed to maintain the approximate dosing time chosen at the beginning of 
the study for their full study participation. Study drug application instructions will be reviewed at subsequent study visits. During subsequent study visits, subjects will apply the daily dose of 
study drug while at the study under the supervision of site personnel, after efficacy and safety DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-[ADDRESS_227901] been completed. The time of th e dose application and as sessments will depend 
on the time of the study visit (either morning or afternoon visit). Therefore, the timing of the 
study visit may lead to a change in the subject’s chosen dosing time; if this occurs, it will NOT 
be considered a protocol deviation; the subject should resume their chosen dosing time the day 
following any such clinic visit application. 
Rescue medications may be initiated with consultation of the medical monitor. 
Safety assessments will include AEs, local (application site) tolerability, clinical laboratory tests, 
vital signs, physical examinations, and invest igator-assessed LTS. Efficacy assessments will 
include a 5-point static PGA (0-4 scale), %BSA af fected, the PASI, and subject-reported DLQI. 
Refer to Section 6 for descriptions of study procedures and assessments and Section  7 and the 
Schedule of Assessments (  
Table 1) for timing of procedures and assessments. 
3.2. Treatment Groups and Duration 
Subjects entering with a PGA ≥ 1 will receive treatment with tapi[INVESTIGATOR_191753], 1% until they 
achieve a PGA score of 0, at which time treatment will be discontinued and subjects monitored 
for durability of response. If or when disease worsening occurs, as evidenced by a PGA ≥ 2, 
treatment will then be re-initiated and continue d until a PGA of [ADDRESS_227902] treatment discontinue d and be monitored for durability of response. 
If/when disease worsening occurs, as evidenced by a PGA ≥ 2, treatment will then be re-initiated 
and continued until a PGA of 0 is observed.  (Section  [IP_ADDRESS]). 
A subject will be considered to have completed the study when he/she completes all required procedures/visits for the 40-week (Visit 11) treat ment period. The end of the study is defined as 
when the last active subject has completed the Follow-up Visit. DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-[ADDRESS_227903] meet all of the following criteria to be eligible to be enrolled in this study: 
1. Completed the 12-week treatment pe riod in 1 of the 2 pi[INVESTIGATOR_36491] 
(Study DMVT-505-3001 or Study DMVT-505-3002)  
2. Male or female 
3. Female subjects of child-bearing potential and male subjects who are engaging in sexual 
activity that could lead to pregnancy should use one of the following acceptable birth 
control methods while on study and for [ADDRESS_227904] exposure to study drug.  Acceptable contraception methods are: 
x Female subject or male subject’s female partner is surgically sterile (bilateral tubal 
ligation, hysterectomy, bilateral oophorectomy) for a minimum of [ADDRESS_227905]’s female partner has had an intrauterine device in 
place for at least [ADDRESS_227906] dose of study drug 
x Double barrier methods (e.g., condom plus diaphragm, condom or diaphragm plus spermicide) starting at least [ADDRESS_227907] dose of study drug 
x Subjects who claim abstinence as their me thod of contraception are allowed provided 
they agree to use a double barrier method (e.g., condom plus diaphragm, condom or diaphragm plus spermicide) should they become sexually active from Screening to [ADDRESS_227908]’s partner (vasectomy) a 
minimum of [ADDRESS_227909]’s female partner is taking hormonal contraceptives 
starting at least [ADDRESS_227910] agree to use a double barr ier method (e.g., condom plus diaphragm, 
condom or diaphragm plus spermicide) from Screening through [ADDRESS_227911] label. The Investigator is responsible for ensuring that subjects understand how to properly use these methods of contraception. DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 28 Non-CBP is defined as premenarchal or premenopausal females with a documented 
bilateral tubal ligation, bilateral oophorectomy (removal of the ovaries) or hysterectomy, or hysteroscopic sterilization; or postmenopausal females defined as a cessation of 
menses for at least 12 months without an alte rnative medical cause. In questionable cases 
a blood sample with simultaneous folli cle stimulating hormone (FSH) >40 ml/U is 
confirmatory. Documented verbal history from the subject is acceptable. 
Female subjects of CBP must have  a negative urine pregnancy tes t at Baseline (Day 1), as 
collected from Week 12 of 1 of the 2 pi [INVESTIGATOR_36491] (Study DMVT-505-3001 or 
Study DMVT-505-3002). 
4. Capable of giving signed informed consent,  as applicable, which includes compliance 
with the requirements and restrictions listed in the informed consent form (ICF); written 
informed consent must be obtained prior to any study related procedures. 
4.3. Exclusion Criteria 
Any subject who meets any of the following criteria will be ineligible to be enrolled in this 
study: 
1. Used a prohibited concomitant product or pro cedure to treat psoriasis during pi[INVESTIGATOR_45880] 
2. Had an SAE that was potentially related to treatment or experienced an AE that led to 
permanent discontinuation of treatment in the pi[INVESTIGATOR_2397] 
3. History of or ongoing serious illness or medical, physical, or psychiatric condition(s) that, in the I nvestigator’s opi[INVESTIGATOR_1649], may interfere with the subject’s completion of the study 
4. Known hypersensitivity to tapi[INVESTIGATOR_191792] 
4.4. Lifestyle Restrictions 
Subjects should avoid prolonged exposure to natural or artificial sources of ultraviolet (UV) 
radiation (e.g., sunlight or tanning booth) and UV light therapy during this study, because UV light may affect the subject ’s psoriasis. The use of sunscreen on nonlesional areas is allowed.  
4.5. Screening Failure 
Screen failures are defined as subjects who consent to participate in the clinical study but are not 
subsequently enrolled. A minimal set of screen  failure information is required to ensure 
transpi[INVESTIGATOR_191793]. Minimal information includes demography, screen failure details, eligibility criteria, and any SAEs. These data will also be linked to subject data from the initial study. 
4.6. Withdrawal Criteria 
A subject may voluntarily discontinue treatment and/or withdraw from participation in this study at any time at his/her own request, or may be discontinued from study treatment at any time at 
the discretion of the Investigator for safety, behavioral, compliance, or administrative reasons. 
Subjects withdrawn from the study will not be replaced. DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 29 4.6.1. Reasons for Withdrawal from Study 
Study drug will be discontinued for any of the following reasons: 
x Subject has an AE that is considered to be related to study drug or procedures AND is 
severe enough to warrant treatment discont inuation, as determined by [CONTACT_737] 
(Section 8.1) 
x Subject requires concurrent prohi bited concomitant medication during the study. If, in 
the opi[INVESTIGATOR_191794], such medication will 
not interfere with the conduct or interpretation of the study or compromise the safety 
of the subject, then the subject may continue to receive study drug. If the subject is discontinued from study drug, they may remain in the study for safety assessments as needed, at the discretion of the Investigator and Medical Monitor. 
x Pregnancy 
x Any Grade 3 or 4 AE considered causally related to study drug (Section 8.2.2) 
Study drug may be discontinued for any of the following reasons: 
x Subject noncompliance 
x Investigator noncompliance 
x Discontinuation of the study at the request of the Sponsor, regulatory agency, or an Institutional Review Board (IRB)/Independent Ethics Committee (IEC) 
If a subject meets a withdrawal criterion during treatment, an Early Termination Visit will be required (Section  7.7). 
4.6.2. Temporary Discontinuation 
A subject will discontinue study drug when th e Investigator determines a PGA of 0 has been 
achieved as described in Section  [IP_ADDRESS]. While actively treating an epi[INVESTIGATOR_191795] a PGA ≥ 2, there are no specific provisions for temporary 
discontinuation of treatment during this study, with the exception of the interruption of study treatment for skin irritation (see Section  1.3). If study treatment is interrupted due to a safety 
issue, the Medical Monitor will be contact[CONTACT_191832] (eCRF). 
4.6.3. Withdrawal Procedures 
The primary reason for the discontinuation of st udy drug and/or withdrawal from study must be 
recorded in the source document and on the eCRF. If a subject is prematurely discontinued from 
study drug(s), the Investigator must make every effort to perform an Early Termination Visit 
(Section  7.7) and document the primary reason for withdrawal. 
Should a subject fail to attend a required study visit, the site should attempt to contact [CONTACT_191833]-schedule the missed visit as soon as possible. The site should also counsel the subject on 
the importance of maintaining the assigned visit schedule and ascertain whether the subject wishes to and/or should continue in the study based on previous non-compliance. In cases where 
the subject does not return for the rescheduled  visit or cannot be reached to reschedule the DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-[ADDRESS_227912] so that they can 
appropriately be withdrawn from the study with a primary reason of “Lost to Follow-up.”  
4.7. Lost to Follow-up 
A subject will be considered lost to follow-up if  he/she repeatedly fails to return for scheduled 
visits and is unable to be contact[CONTACT_9298]. The following actions must be taken if a subject fails to return to the clinic for a required study visit: 
x The site must attempt to contact [CONTACT_191834]/or should continue in the study. 
x Before a subject is deemed lost to follow-up, the Investigator or designee must make every effort to regain contact [CONTACT_1155] (where possible, [ADDRESS_227913]’s last known mailing address or local 
equivalent methods). These contact [CONTACT_9300]’s medical record. 
x Should the subject continue to be unreachable , he/she will be considered to have 
withdrawn from the study with a primary reason of lost to follow-up. DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 31 5. STUDY TREATMENT 
5.1. Study Drug 
5.1.1. Description, Packaging, and Labeling 
The description of the study drug is presented in Table 2 . 
Table 2 Tapi[INVESTIGATOR_191796]: DMVT-505 (tapi[INVESTIGATOR_191752]) 
Physical description White to off-white cream 
Unit dose strength/how supplied 1% (10 mg/g)/30 gram, tube 
Route of administration/duration Topi[INVESTIGATOR_2855]/up to 40 weeks 
Dosing instructions: Once daily topi[INVESTIGATOR_191797] (see Section  5.1.5)  
Manufacturer GlaxoSmithKline 
 
Study drug will be dispensed to subjects at th e clinical site in appropriately labeled tubes. All 
labels for tapi[INVESTIGATOR_191753], 1% to be distributed in the participating countries will meet all 
applicable requirements of those countries. 
5.1.2. Storage 
All study drug must be stored in a secure e nvironmentally-controlled a nd monitored (manual or 
automated) area in accordance with the labelled storage conditions, with access limited to the 
Investigator and authorized site staff. 
5.1.3. Handling and Disposal 
Under normal conditions of handling and administration, study drug is not expected to pose 
significant safety risks to site staff. In the case of unintentional occupational exposure notify the 
monitor, Medical Monitor and/or the Sponsor study contact. 
A Material Safety Data Sheet (MSDS)/equivalent doc ument describing occupational hazards and 
recommended handling precautions either will be provided to the Investigator, where this is 
required by [CONTACT_1207], or is available upon request from the Sponsor. 
Arrangements will be made for used and unused drug supplies to be returned to the Sponsor or 
Sponsor designee, or for destruction on site following acceptable, documented procedures. 
Further guidance and information for final disposition of unused study drug will be provided. DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 32 5.1.4. Preparation 
No special preparation of study drug is required. 
5.1.5. Administration of Study Drug 
[IP_ADDRESS]. Treatment by [CONTACT_191835] a PGA ≥ 1 will receive treatment with tapi[INVESTIGATOR_191753], 1% until they 
achieve a PGA score of 0 .  If/when disease worsening occurs, as evidenced by a PGA ≥ 2, 
treatment will then be re-initiated and continue d until a PGA of [ADDRESS_227914] treatment discontinue d and be monitored for durability of response. 
If/when disease worsening occurs, as evidenced by a PGA ≥ 2, treatment will then be re-initiated 
and continued until a PGA of 0 is observed. This treatment and re-treatment pattern of use will 
be continued until the end of the study (i.e., subjects may receive study treatment up until the 
Week 40 visit).   Subjects who experience suspected disease worsening between scheduled study visits may contact [CONTACT_191836] (Section  7.5). See Disease Worsening 
(PGAt
t2) During the Study  (Section  [IP_ADDRESS]) for further instructions. Upon confirmation of 
disease worsening, subjects will restart treatment with study drug. 
[IP_ADDRESS]. Disease Worsening (Physician Global Assessment Score ≥  2) During the Study 
If disease worsening is suspected between sche duled study visits, an unscheduled visit may 
be performed. 
x If disease worsening (ie, PGA ≥ 2) is not confirmed, the subject will continue to be 
assessed at routine, scheduled visits (see Table 1 ). 
x For each confirmed epi[INVESTIGATOR_191798] (ie, PGA ≥ 2) during the study (at 
either a scheduled or unscheduled visit), a treatment course of tapi[INVESTIGATOR_191753] (once 
daily) will be initiated and will continue until the subject achieves a PGA 0, as 
assessed at scheduled visits, approximately every 4 weeks (see Table 1 ). 
x Subjects subsequently achieving a PGA of 0 will stop study drug and will then be assessed at routine, scheduled visits (see  
x Table 1). Subjects who then experience suspected disease worsening between 
scheduled study visits may contact [CONTACT_191836] (see  
x Table 1). 
 If disease worsening is not confirmed, the subject will continue to be assessed at 
routine, scheduled visits. 
 If disease worsening is confirmed (ie, PGA ≥ 2) at either an unscheduled or a 
scheduled visit, subjects will initiate a nother treatment course of tapi[INVESTIGATOR_191753] 
(once daily) until a PGA 0 is achieved as described above. 
x This treatment and re-treatment pattern of use will be continued until the end of the 
study (ie, subjects may receive study treatment up until the Week 40 visit). DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 33 [IP_ADDRESS]. Application of Study Drug 
Study drug will be dispensed to subjects requiri ng treatment at the study visits specified in the 
Schedule of Assessments (  
Table 1). 
Subjects will take the tubes home and self-admin ister (or have a caregiver apply if necessary), 
except on study visit days (when study drug is appl ied under supervision at the site), to affected 
areas once daily. 
Subjects will be instructed to apply study drug as follows: 
x For subjects with a PGA > 0, once daily application to affected areas including those 
areas treated in the pi[INVESTIGATOR_2397]; subject s are to choose the application time they 
prefer and to apply the study drug at that time each day of study participation. 
x Subjects with a PGA of 0 will not receive tr eatment but if they worsen and experience 
a PG A of ≥ 2, apply once daily to newly affected areas only.  
x If a subject misses a daily dose, it will  be recorded as a protocol deviation. The 
subject should continue dosing the next day and should not apply more than once daily to make up for the missed dose on the previous day. 
x If chosen application time is in the evening, the dose should be applied at least [ADDRESS_227915] improved during the study. 
x Subjects are allowed, but not required, to treat fingernails, toenails, palms, soles, and scalp lesions with study drug; however, efficacy analyses will not include assessment of improvement of psoriasis in these areas). If using study drug on the scalp, no other treatment for scalp psoriasis is permitted during the study. 
x If there is residual cream visible on the dise ase-affected lesional skin, then the subject 
should be instructed to continue to lightly rub the cream into the skin until it is no longer visible 
x If study drug is applied to the subject by [CONTACT_19015], that person should thoroughly wash his/her hands after application. When possible, use of disposable gloves is recommended. 
x Subjects should record the time of study drug application in the daily diary. 
x Subjects should avoid swimming, bathing, showering, or strenuous activities for at 
least [ADDRESS_227916] been completed NOTE: The time of the dose and assessments on study visit days will depend on the 
time of the study visit (either morning or afternoon visit). Therefore, the timing of the 
study visit may differ from the subject’s chosen dosing time (morning or evening); if DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-[ADDRESS_227917] should 
resume their chosen dosing time following any such study visit. The intention is to 
allow flexibility to accommodate subjects’ schedules.  
5.2. Randomization/Treatment Assignment 
All subjects will receive treatment with tap inarof cream, 1% as needed per protocol. 
5.3. Blinding 
This study is an open-label study; blinding is not applicable. 
5.4. Compliance with Study Drug Administration 
At baseline, study staff will provide the subjec t with detailed instructions concerning protocol 
requirements and use of study drug in this extension study. Additionally, subjects will be asked 
to complete a daily diary with the time of each application of study drug. At each postbaseline 
study visit, study staff will review use of study drug, as applicable, with the subject. 
When subjects are dosed at the site, they will apply the study drug under supervision of the study 
staff. The date and time of each dose administered in the clinic will be recorded in the source 
documents. The study drug and study subject iden tification will be confirmed at the time of 
dosing by a member of the study site staff. 
At the time of dispensing study drug to each subject, site personnel will weigh the tubes to be 
dispensed and will record the weight of all tubes dispensed at each visit in the drug 
accountability logs. Subjects will be instructed to bring all used and unused tubes with them to 
each study visit. Site personnel will weigh th e returned tubes (used a nd unused) and record the 
weight in the drug accountability logs. If a tube has been lost, discarded, or forgotten by [CONTACT_1560], the site personnel will make a notation of this on the drug accountability logs. The site 
personnel will remind the subject to keep all tubes of study drug dispensed and to bring all used 
and unused tubes to each study visit. These data wi ll be used to estimate subject compliance with 
use of study drug. Tubes of study medication disp ensed at the most recent prior visit, which 
remain unopened (the foil cap on the tube remains fully intact/undisturbed) may be redispensed to study subjects at the current visit. Unopened tubes may only be dispensed one time. Opened, partially used tubes, or tubes with foil overlay removed are not to be redispensed to study 
subjects. If there is any question as to redispensation, sites should issue new tubes of study 
medication to the subject(s). 
5.5. Treatment after the End of the Study 
Subjects will not receive any additional treatment with the study drug from the Sponsor after completion of the study. The indication being studied is not life threatening or seriously 
debilitating, and other treatment options are available.
 
The Investigator is responsible for ensuring that consideration has been given to the poststudy care of the subject’s medical condition, whether or not the Sponsor is providing specific 
poststudy drug. DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 35 5.6. Prior and Concomitant Therapy 
 
The Medical Monitor should be contact[CONTACT_63193]. 
5.6.1. Permitted Medications and Nondrug Therapi[INVESTIGATOR_191799], under the 
condition that the dosage and administration of these treatments is not planned to change from 
the Baseline visit to the completion of the stud y or discontinuation, and that the medication is not 
a prohibited medication as described in Section  5.6.2 . In the event of skin infection, topi[INVESTIGATOR_191800]; however, study drug must not be applied 
to the area until the skin infection is healed. 
Subjects may use nonmedicated shampoos (must not contain corticosteroids, vitamin D analogs, 
salicylic acid, or coal tar). Nonm edicated emollients may be used on nonlesional skin; emollients 
should not be applied to lesional skin during acti ve treatment courses and should not be applied 
on the morning of study visits. The same emollient should be used throughout the subject’s 
participation in the study. 
Note: Any emollient used during the study must  be recorded as a concomitant medication. 
5.6.2. Prohibited Medications and Nondrug Therapi[INVESTIGATOR_191801]: 
x Biologic agents:  rituximab, ustekinumab, secukinumab, golimumab, ixekizumab, 
infliximab, adalimumab, alefacept, etanercept (list is not exclusive, contact [CONTACT_191837]) 
x Systemic treatments:  cyclosporin, interferon, methotrexate, apremilast, tofacitinib, 
mycophenolate, thioguanine, hydroxyurea, sirolimus, azathioprine, other systemic immunosuppressive or immunomodulating agents, fumaric acid derivatives, vitamin D3 and analogs (>5000 IU / day), retinoids (e.g., acitretin, isotretinoin), psoralens, corticosteroids, or adrenoc orticotropic hormone analogs 
x Ultraviolet light:  therapy or prolonged exposure to natural or artificial sources of UV 
radiation (e.g., phototherapy, tanning beds/booths, or therapeutic sunbathing) 
x Topi[INVESTIGATOR_12969]:  corticosteroids, antihistamines, immunomodulators, anthralin 
(dithranol), Vitamin D derivatives (e.g.,  calcipotriene, calcipotriol), retinoids 
(e.g., tazarotene), or coal tar 
x Drugs known to possibly worsen psoriasis (unless on a stable dose for 
>12 weeks):  beta blockers (e.g., propranolol), lithium, iodides, angiotensin-
converting enzyme inhibitors, and indomethacin 
x Immunizations: live, attenuated vaccines (inactivated or subunit vaccines are 
acceptable when required) 
x Other: any Investigational products or procedures DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 36 6. STUDY ASSESSMENTS AND PROCEDURES 
Study procedures and assessments are summar ized in the Schedule of Assessments ( Table 1 ) and 
in Section 7. Adherence to the study design requirements, including those specified in the 
schedule of activities, is essential and requi red for study conduct. Protocol waivers or 
exemptions are not allowed. 
6.1. Medical History and Demography 
6.1.1. Medical History 
Medical, medication, and family history collec ted during the pi[INVESTIGATOR_191802]. 
6.1.2. Demographics 
The demographic information collected during the pi [INVESTIGATOR_191803], 
including: age, sex, race, and ethnicity. 
6.2. Efficacy Assessments 
To minimize interobserver variability, investigators and evaluators/raters will be trained on each 
of the required assessments during an investigator meeting, site initiation visit, and/or utilizing 
online assessments before enrolling subjects at thei r study center. Only trained evaluators/raters 
are permitted to perform the efficacy assessments. To the fullest extent possible, the same 
investigator (or designated evaluator/rater) will perform all efficacy assessments for an 
individual subject throughout the study. If it is  not possible for the same evaluator/rater to 
continue performing assessments, it is re commended that the primary and subsequent 
evaluator/rater both examine and discuss their respective scoring during at least 1 visit. 
6.2.1. Assessments by [CONTACT_10670] 
[IP_ADDRESS]. Physician Global Assessment 
The PGA is a clinical tool for assessing the current state/severity of a subjec t’s psoriasis  at a 
given timepoint. It is a static 5-point morphologic al assessment of overall disease severity, as 
determined by [CONTACT_737], using the clinical characteristics of erythema, scaling, and plaque 
thickness/elevation as guidelines; higher PGA scores represent more severe disease. The BSA 
affected is not considered in scoring of the PGA (see Section [IP_ADDRESS]). Variations of the PGA are 
frequently used in clinical studies because it is  a simple assessment that is more similar to the 
assessments actually used in clinical practice (see Appendix 1 for details). The PGA should be 
performed first, prior to %BSA, PASI, and LTS assessments. DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 37 [IP_ADDRESS]. Body Surface Area 
The assessment of the %BSA is an estimate of the percentage of total involved skin with 
psoriasis. For the purpose of clinical estimation, th e total palmar surface of the subject’s palm  
and digits may be assumed to be approximately e quivalent to 1% BSA. The %BSA affected by 
[CONTACT_191838] (from 0 to 100%). Details on calculation of approximate %BSA involvement in each subject (total and individual are provided in Appendix 2) . Percentage BSA 
is a static assessment made without reference to previous scores. 
Note: for all efficacy assessments, lesions on the subject’s scalp, palms, fingernails, toenails, and 
soles will not be included in the calculation of %BSA affected as these areas will not be included 
in the efficacy analyses. 
[IP_ADDRESS]. Psoriasis Area and Severity Index 
The PASI scoring system is a widely-used standard clinical tool for assessing the severity of 
psoriasis that takes into account the overall se verity of erythema (redness), induration (plaque 
thickness), and scale, and the extent of %BSA af fected with psoriasis. The 3 clinical signs are 
each graded on a 5-point scale (0 to 4) and the %BSA affected is scored on a 7-point scale (0 to 6) for each of the 4 specified body regions (head, upper extremities, trunk, and lower extremities). The individual scores are multiplied by a weighted factor for each body region; the 
sum of these scores gives the overall PASI score. Higher scores indicate more severe disease. 
PASI is a static assessment made without reference to previous scores. See Appendix 2. 
6.2.2. Assessments Completed by [CONTACT_27720]  
[IP_ADDRESS]. Dermatology Life-Quality Index 
Subjects will complete the DLQI questionnaire. The DLQI is simple dermatology-specific 
10-question validated questionnaire to assess the impact of the disease on a subject’s quality 
of life (Cardiff University, Department of Dermatology, Quality of Life Questionnaires). 
The DLQI has become an important outcome measure in dermatology clinical trials and is the most frequently used instrument in studies of randomized controlled trials in dermatology 
[Basra, 2015]. The DLQI can be analyzed as a total score (where a higher score indicates greater 
impairment in quality of life) and can also be scored for the following dimensions: Symptoms 
and Feelings (items 1 and 2), Daily Activities (items 3 and 4), Leisure (items 5 and 6), Work and 
School (item 7), Personal Relationships (items 8 and 9), and Treatment (item 10). An example of 
this assessment is provided Appendix 3. For additional information, refer to the Study Reference 
Manual. 
[IP_ADDRESS]. Patient Satisfaction Questionnaire 
Subjects will complete the Patient Satisfac tion Questionnaire. The Patient Satisfaction 
Questionnaire is provided in Appendix 5. 
6.2.3. Optional Clinical Photography 
Clinical photography may be performed in a subgroup of subjects at selected study centers that 
participated in photography in the pi[INVESTIGATOR_2397]. This is not required of subjects for participation DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-[ADDRESS_227918]’s disease area at the time points 
specified in the Schedule of Assessments (Table 1; see also section 7). Three photographs of the 
selected skin area will be taken in a standardized fashion (ie, same camera, angle, background, distance). Procedures for the clinical photography w ill be contained in the Photography Manual. 
6.3. Safety Assessments 
6.3.1. Adverse Events 
All AEs will be collected from the time the subjec t signs the ICF until the final visit/contact [CONTACT_191839]. Adverse events that began during the pi[INVESTIGATOR_191804]. Additional safety information, including the 
definition of an AE and the methods for recording, evaluating, and assessing causality of AEs 
and the procedures for completing and transm itting SAE reports are provided in Section  8. 
6.3.2. Brief Physical Examination 
A brief physical examination will include, at a minimum, assessments of the skin, lungs, 
cardiovascular system, and abdomen (liver and spleen). Investigators should pay special 
attention to clinical signs related to previous serious illness. 
6.3.3. Vital Signs 
Vital signs will be measured before blood collecti on for clinical laboratory assessments and will 
include measurements of systolic and diastolic blood pressure, pulse rate, and body temperature. 
Subjects should be in a seated position for at least [ADDRESS_227919] 
number, protocol number, site/center number, and visit date. Details for the preparation and 
shipment of samples will be provid ed by [CONTACT_191840]. Reference ranges for all safety parameters will be provided to 
the site by [CONTACT_91007]. 
A list of clinical laboratory tests and parameters is provided in Table 3 . 
All laboratory tests with values that are considered clinically significantly abnormal during 
participation in the study should be repeated until the values return to normal or baseline. If such 
values do not return to normal within a period judged reasonable by [CONTACT_737], the etiology should be identified, if possible, and the Sponsor notified. DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 40 6.3.5. Local Tolerability Scale 
At each specified study visit and if the subjec t is receiving study drug, the Investigator (or 
qualified evaluator) will assess the presence and overall degree of irritation at the application 
sites, according to the LTS (an example of the LTS is provided in Appendix 4). The score will 
ideally represent an ‘average’ across all application sites. To the fullest extent possible, the same 
Investigator (or designated evaluator) will perform all tolerability assessments for an individual subject throughout the study. If the subject is applying study treatment to “sensitive areas” 
(e.g., genitals, face, neck, and skin folds), then the degree of irritation for these areas should also 
be assessed by [CONTACT_093]. 
Additionally, at each specified study visit if re ceiving study drug, the subject will use a 5-point 
LTS to assess the presence and degree of burning/stinging and itching at the treatment areas. The 
score will ideally represent an ‘average’ across all application sites . 
6.4. Treatment of Study Drug Overdose 
For this study, accidental or intentional ingestion of the study drug is considered an overdose. 
Ingestion of a 30-gram tube of 1% cream w ould result in an oral dose of 300 mg. 
The Sponsor does not recommend specific treatment for an overdose. 
In the event of an overdose, the Investigator (or treating physician) should: 
x Contact [CONTACT_191841] 
x In the event of excessive topi[INVESTIGATOR_191805], instruct the subject to wash study drug 
off of the skin and monitor for application-site AEs. 
x Monitor subject for systemic AEs/SAEs and clinically significant laboratory 
abnormalities. 
x Obtain blood sample within [ADDRESS_227920] application of study drug or 
date of ingestion to determine possible systemic exposure to study drug (if requested by [CONTACT_1689]; determined on a case-by-case basis) 
x Provide general symptomatic treatment as necessary 
x Document quantity of excess dose (e.g., by [CONTACT_191842]) and duration of exposure, in the eCRF. 
Decisions regarding dose interruptions or modifications will be made by [CONTACT_191843]. 
6.5. Pharmacokinetics/Pharmacodynamics 
Pharmacokinetics/pharmacodynamics will not be performed in this study. DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 41 7. TIMING OF PROCEDURES AND ASSESSMENTS 
This section lists the procedures and assessment to be performed at scheduled timepoints during 
the study as outlined in the Schedule of Assessments ( 
Table 1). Information on study procedures and assessments is provided in Section  6. 
x Any change in timing or any addition of a time point(s) for any planned study 
assessment must be documented in a “Note to File,”  which is approved by [CONTACT_191844]; this will NOT c onstitute a protocol amendment. 
x The IRB/IEC will be informed of any safety issues that require alteration of the safety monitoring scheme or amendment of the ICF. 
NOTE: Assessments and procedures should be performed predose on study visit days. 
7.1. Visit 1; Baseline 
On Day 1, subjects from the pi[INVESTIGATOR_191806]. All subjects who 
continue to meet study eligibility criteria will be enrolled. Subjects entering with a PGA ≥ 1 will 
receive treatment with tapi[INVESTIGATOR_191753], 1% until  they achieve a PGA score of 0, at which time 
treatment will be discontinued and subjects m onitored for durability of response.  If/when 
disease worsening occurs, as evidenced by a PGA ≥ 2, treatment will then be re -initiated and 
continued until a PGA of [ADDRESS_227921] treatment 
discontinued and be monitored for durability of response  
The following procedures and assessments will be performed at the Baseline Visit: 
x Brief physical exam (last assessment from pi[INVESTIGATOR_2397]) 
x Vital signs measurements (last assessment from pi[INVESTIGATOR_2397]) 
x Urine pregnancy test (females of CBP; last assessment from pi[INVESTIGATOR_2397]) 
x Blood sample collection for clinical laborator y tests (serum chemistry, hematology, 
diagnostic tests; last assessment from pi[INVESTIGATOR_2397]) 
x Urinalysis  
x Photography of a representative area of the subject’s disease area (optional for 
subjects; at a subset of study centers) (last assessment from pi[INVESTIGATOR_2397]) 
x PGA score (last assessment from pi[INVESTIGATOR_2397]) 
x BSA affected calculation (last assessment from pi[INVESTIGATOR_2397]) 
x PASI (last assessment from pi[INVESTIGATOR_2397]) 
x DLQI (last assessment from pi[INVESTIGATOR_2397]) 
x AE recording (Including any ongoing AEs from the pi[INVESTIGATOR_191807]) 
x Concomitant medication recording (from the time ICF is signed) 
x Diary dispensed (subjects will be instructed in how and when to complete diary), if applicable 
x Dispense study drug, if applicable DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 42 x Instruction on how to apply study drug, if applicable 
x Study drug application under supervision, if applicable 
7.2. Visits 2 to 10; Treatment Period 
Subjects entering with a PGA ≥ 1 will receive treatment with tapi[INVESTIGATOR_191753], 1% until they 
achieve a PGA score of 0, at which time trea tment will be discontinued and subjects 
monitored for durability of response.  If/when disease worsening occurs, as evidenced by a 
PGA ≥ 2, treatment will then be re-initiated and continued until a PGA of [ADDRESS_227922]  treatment discontinued and be monitored for 
durability of response . If/when disease worsening occurs, as evidenced by a PGA ≥ 2, 
treatment will then be re-initiated and conti nued until a PGA of [ADDRESS_227923] every 4 weeks (±3 Days) during the 40-week monitoring 
period. The following assessments will be performed:  
x Brief physical exam 
x Vital signs measurements 
x Urine pregnancy test (females of CBP) 
x Blood sample collection for clinical laborator y tests (serum chemistry, hematology, 
diagnostic tests); Weeks 4, [ADDRESS_227924]’s disease area (optional for 
subjects; at a subset of study centers)  
x PGA score 
x BSA affected calculation 
x PASI 
x LTS (if patient has been applying study drug for the treatment period prior to the 
scheduled visit) 
x DLQI 
x AE recording 
x Concomitant medication recording 
x Collect and dispense diary, if applicable (subjects will be instructed in how and when 
to complete diary) 
x Review diary for treatment compliance, if applicable 
x Dispense and collect study drug, if applicable 
x Instruction on how to apply study drug, if applicable 
x Study drug application under supervision, if applicable 
7.3. Visit 11;  
The following procedures and assessments will be performed at the Week 40 Visit: 
 
x Brief physical exam 
x Vital signs measurements DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-[ADDRESS_227925] (females of CBP) 
x Blood sample collection for clinical laborator y tests (serum chemistry, hematology, 
diagnostic tests) 
x Urinalysis 
x Photography of a representative area of the subject’s disease area (optional for 
subjects; at a subset of study centers)  
x PGA score 
x BSA affected calculation 
x PASI 
x LTS (if patient has been applying study drug for the treatment period prior to the 
scheduled visit) 
x DLQI 
x Patient Satisfaction Questionnaire 
x AE recording 
x Concomitant medication recording 
x Collect diary, if applicable  
x Review diary for treatment compliance, if applicable 
x Collect study drug, if applicable 
7.4. Follow-up Visit 
Subjects will return to the study site 4 weeks (± 3 days) after last treatment to complete follow-up 
assessments as follows: 
x Brief physical exam 
x Vital signs measurements 
x Urine pregnancy test (females of CBP) 
x Blood sample collection for clinical laborator y tests (serum chemistry, hematology, 
diagnostic tests) 
x Urinalysis 
x Photography of a representative area of the subject’s disease area (optional for 
subjects; at a subset of study centers) 
x PGA score 
x BSA affected calculation 
x PASI 
x DLQI 
x AE recording 
x Concomitant medication recording DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-[ADDRESS_227926] at Week 2 (Day 15 ±3 Days) 
Subjects will be contact[CONTACT_191845] [ADDRESS_227927] AEs and concomitant medication use.  Subjects should be reminded to complete their daily diary and bring it with them to the next study visit. 
7.6. Unscheduled Visits 
Unscheduled visits may occur, as needed. For subjects who experience suspected disease 
worsening (PGA ≥  2) between scheduled study visits may contact [CONTACT_191846] (see Section  [IP_ADDRESS]). The following assessments will be performed: 
x Brief physical exam 
x Vital signs measurements 
x Urine pregnancy test (females of CBP), as needed 
x Blood sample collection for clinical laborator y tests (serum chemistry, hematology, 
diagnostic tests), as needed 
x Urinalysis, as needed 
x Photography of a representative area of the subject’s disease area (optional for 
subjects; at a subset of study centers)  
x PGA score 
x BSA affected calculation 
x PASI 
x LTS (if patient has been applying study drug for the treatment period prior to the 
scheduled visit) 
x AE recording 
x Concomitant medication recording 
x Collect and dispense diary, if applicable (subjects will be instructed in how and when to complete diary) 
x Review subject diaries for treatme nt compliance, if applicable 
x Collect and dispense study drug (if applicable) 
x Instruction on how to administer  study drug (if applicable) 
x Study drug administration under supervision (if applicable) 
If disease worsening is confirmed, a new treatment course will be initiated. 
7.7. Early Termination 
Subjects who withdraw early from the study will be asked to return to the study site to complete Early Termination assessments as follows: 
x Brief physical exam 
x Vital signs measurements 
x Urine pregnancy test (females of CBP) DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 45 x Blood sample collection for clinical laborator y tests (serum chemistry, hematology, 
diagnostic tests) 
x Urinalysis 
x Photography of a representative area of the subject’s disease area area  (optional for 
subjects; at a subset of study centers) 
x PGA score 
x BSA affected calculation 
x PASI 
x LTS (if patient has been applying study drug for the treatment period prior to the 
scheduled visit) 
x DLQI 
x Patient Satisfaction Questionnaire  
x AE recording 
x Concomitant medication recording 
x Collect and review subject diaries for treatment compliance 
x Collect study drug 
7.8. End of Study 
The end of the study is defined as when the last  active subject has completed the Follow-up Visit 
(Week 44). DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-[ADDRESS_227928] (AESI). At each 
visit/contact, subjects should be questioned in a general way so as not to introduce bias in 
detecting AEs and/or SAE. Open-ended and non-lea ding verbal questioning of the subject is the 
preferred method to inquire about AE occurrence. 
Investigators are not obligated to actively seek AEs or SAEs in former study subjects. However, 
if the Investigator learns of any SAE, including a death, at any time after a subject has been 
discharged from the study, and he/she considers the event reasonably related to the study drug or 
study participation, the Investigator would promptly notify the Sponsor. 
8.1.1. Definition of Adverse Events 
An AE is any untoward medical occurrence in a subject temporally associated with the use of a 
medicinal product, whether considered causally related or not related to the medicinal product. 
An AE can therefore be any unfavorable and uni ntended sign (including an abnormal laboratory 
finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. 
Events that meet the definition of an AE include: 
x Any abnormal laboratory test results (hematology, clinical chemistry) or other safety 
assessments (e.g., vital signs measurements), including those that worsen from 
baseline, and felt to be clinically significant in the medical and scientific judgment of the Investigator 
x Exacerbation of a chronic or intermittent pre-existing condition (e.g., atopic dermatitis) including either an increase in frequency and/or intensity of the condition 
 For skin-related AEs, it should be noted whether or not the event is in the area of 
active application of study medication, and/or if spreading beyond the application site. 
x New conditions detected or diagnosed after study drug administration even though it may have been present prior to the start of the study 
x Signs, symptoms, or the clinical sequelae of a suspected interaction 
x Signs, symptoms, or the clinical sequelae of a suspected overdose of either study drug or a concomitant medication (overdose per se will not be reported as an AE/SAE) 
x "Lack of efficacy" or "failure of expected pharmacological action" per se will not be reported as an AE or SAE. Such inst ances will be captured in the efficacy 
assessments. However, the signs, symptoms, and/or clinical sequelae resulting from lack of efficacy will be reported as AE or SAE if they fulfill the definition of an AE or SAE. DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 47 x Symptomatic complaints at the site of local application (e.g., burning/stinging, 
pruritus, erythema) 
Events that do not  meet the definition of an AE include: 
x Any clinically significant abnormal laboratory findings or other abnormal safety assessments associated with the underlying disease, unless judged by [CONTACT_191847] s ubject’s condition  
x The disease/disorder being studied or expected  progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the subject’s 
condition 
x Medical or surgical procedure (e.g., endoscopy, appendectomy); the condition that leads to the procedure is an AE 
x Situations where an untoward medical occurrence did not occur (social and/or convenience admission to a hospi[INVESTIGATOR_307]) 
x Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or detected at the start of the study that do not worsen 
8.1.2. Definition of Serious Adverse Event 
If an event is not an AE per Section 8.1.1, then it cannot be an SAE even if serious conditions are 
met (e.g., hospi[INVESTIGATOR_1080]/symptoms of the disease under study, death due to progression of disease, etc.). 
An SAE is any untoward medical occurrence that, at any dose: 
x Results in death 
x Is life-threatening 
 The term “life -threatening”  refers to an event in which the subject was at risk of 
death at the time of the event; does not refer to an event, which hypothetically 
might have caused death, if it were more severe. 
x Requires hospi[INVESTIGATOR_1081] 
 In general, this signifies that the subject has been detained (usually involving at 
least an overnight stay) at the hospi[INVESTIGATOR_22771]/or treatment that would not have been appropriate in the physician’s office or 
out-patient setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a complication prolongs hospi[INVESTIGATOR_9236], the 
event is serious. When in doubt as t o whether “hospi[INVESTIGATOR_059]” occurred or  was 
necessary, the AE should be considered serious 
Hospi[INVESTIGATOR_5187] a pre-existing condition that did not worsen from baseline is not considered an AE. 
x Results in disability/incapacity: a substantial disruption of a person’s ability to conduct normal life functions 
 This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 48 influenza, and accidental trauma (e.g., sprained ankle), which may interfere or 
prevent everyday life functions but do not constitute a substantial disruption. 
x Results in a congenital anomaly/birth defect 
x Medical or scientific judgment should be exercised in deciding whether reporting is appropriate in other situations, such as important medical events that may not be immediately life-threatening or result in death or hospi[INVESTIGATOR_191808]. These should also be considered serious. Examples of such events are invasive or ma lignant cancers, intensive treatment in an 
emergency room or at home for allerg ic bronchospasm, blood dyscrasias, or 
convulsions that do not result in hospi[INVESTIGATOR_18543], or development of drug dependency 
or drug abuse. 
8.1.3. Adverse Events of Special Interest 
In prior clinical studies, the following AEs have been identified as AEs of particular clinical importance and will be reported as AESIs in this study; in each case, study drug may be discontinued, and study drug may be restarted when event resolves: 
x Contact [CONTACT_8748]: the study site should collect location, duration, size, associated 
symptoms (itching, burning, pain), severity (mild, moderate, severe), and photograph the affected site (if possible). If the subjec t contacts the study site to report significant 
skin irritation at or near the site of study drug application between study visits, the subject should be brought for an unscheduled visit, if possible. 
x Folliculitis: the study site should collect  the location, duration, size, associated 
symptoms (itching, burning, pain), severity (mild, moderate, severe), indicate whether pustular, and photograph the aff ected site (if possible) 
x Headache: the study site should collect duration, severity (mild, moderate, severe), 
onset, and location  
Additional AESIs may be identified by [CONTACT_191848]. For each AESI, a narrative may be written  and included in the Clinical Study Report. 
8.2. Classification of Adverse Events 
8.2.1. Assigning Severity Rating for Adverse Events 
[IP_ADDRESS]. Criteria for Determining Adverse Event Severity 
The Investigator will make an assessment of the severity of each AE and SAE according to the 
National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), v. 5.0, 
2017. For terms not specified with the CTCAE, the criteria in Table 4  should be used to 
determine the grade severity. DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 49 Table 4: Criteria for Determining the Gr ade/Severity of Adverse Event Terms Not 
Specified by [CONTACT_191849] 
1 Mild; asymptomatic or mild symptoms, clinical or diagnostic observations only; intervention not 
indicated 
2 Moderate; minimal, local, or noninvasive interven tion indicated; limiting age-appropriate instrumental 
activities of daily livinga 
3 Severe or medically significant but not immediately  life-threatening; hospi[INVESTIGATOR_24599]; disabling; limiting self-care activities of daily livingb 
4 Life threatening consequences; urgent intervention indicated 
5 Death related to adverse event 
CTCAE = Common Terminology Criteria for Adverse Events. 
a  Instrumental activities of daily living refer to prepar ing meals, shoppi[INVESTIGATOR_3112], using the 
telephone, managing money, etc. 
b  Self-care activities of daily living refer to bathing, dressing and undressing, feeding self, using the toilet, taking 
medications, and not bedridden. 
 
Adverse event severity should be recorded in th e appropriate section of the adverse event case 
report form and in the subject’s source documents.  
[IP_ADDRESS]. Toxicity Management Criteria 
[IP_ADDRESS].1. Grade [ADDRESS_227929] 
study withdrawal / follow-up evaluations completed. 
[IP_ADDRESS].2. Grade 3 Adverse Event 
Subjects who develop a Grade 3 AE should be managed as follows: 
x If the Investigator has compelling evidence that the Grade [ADDRESS_227930] withdrawal 
study evaluations completed. 
[IP_ADDRESS].3. Grade [ADDRESS_227931] withdrawal study 
evaluations completed. DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 50 [IP_ADDRESS].4. Other Management Criteria 
The Medical Monitor should be notified if any of the following occur: 
x Severe signs or symptoms, or significant changes in any of the safety assessments, 
that put the safety of the subject at risk (e.g., laboratory tests or vital signs, etc.) as judged by [CONTACT_737] 
8.2.2. Assigning Causal Relati onship to Study Drug 
An Investigator is to make the causality assessment. Causality assessment may only be delegated to a Principal Investigator [INVESTIGATOR_54720]-Investigator; howe ver, if it is de legated to any other staff, this 
must be recorded as a protocol deviation. The reasonable possibility of the relationship of an 
adverse event to study drug is to be assessed with careful medical consideration at the time of 
evaluation of an adverse event. The following de finitions are to be used for the relationship of 
the adverse event to study drug: 
x Related : A clinical event, including laboratory test abnormality, with a temporal 
relationship to study drug administration th at makes a causal relationship plausible, 
unlikely attributed to concurrent disease or other drugs or chemicals, and that follows 
a clinically reasonable response on readministration (rechallenge) with or withdrawal (dechallenge) from study drug, although information on drug withdrawal may be lacking or unclear 
x Not related : A clinical event, including laboratory test abnormality, with a temporal 
relationship to study drug administration that makes a causal relationship improbable and/or in which other drugs, chemicals, or underlying disease provide a plausible 
explanation 
Any AEs/SAEs assessed as related to study par ticipation (e.g., protocol-mandated procedures, 
invasive tests, or change in existing therapy) or related to study drug will be collected from the 
time a subject consents to participate in the study up to and including any follow-up contact. 
All AEs, whether related to study drug or not, must be fully and completely documented on the 
AE page of the eCRF and in the s ubject’s clinical record. In the event a subject is withdrawn 
from the study because of an adverse event, th e primary reason for withdrawal (e.g., due to an 
adverse event) must be recorded on the eCRF as such. 
8.3. Time Period and Frequency for Event Assessment and Follow-up 
8.3.1. Adverse Event Reporting 
All AEs will be collected from the time of si gned informed consent until the final visit. 
Any AEs assessed as related to study participat ion (e.g., protocol-mandated procedures, invasive 
tests, or change in existing therapy) will be collected from the time a subject consented to 
participate in the study up to and including any follow-up contact. 
All SAEs will be recorded in the eCRF and repo rted to the Sponsor within 24 hours via email or 
phone (refer to Medical Monitor/Sponsor Information page for contact [CONTACT_3031]) 
(see Section  8.4). DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 51 8.3.2. Follow-up of Adverse Events 
After the initial AE/SAE report, the Investigator is required to proactively follow each Subject at 
subsequent visits/contacts. All SAEs and nonseri ous AEs will be followed until resolution, until 
the condition stabilizes, until the event is otherw ise explained, or until the subject is lost to 
follow-up. 
The Investigator will assess the outcome of each AE using the following criteria: 
x Recovered/Resolved: The event has improved or subject recuperated. 
x Recovered/Resolved with sequelae:  The subject has recuperated but retained 
pathological conditions resulting from the prior disease or injury. 
x Recovering/Resolving:  The event is improving. 
x Not recovered/Not resolved:  The event has not improved or subject recuperated. 
x Unknown:  The outcome of the event is not known, not observed, not recorded, or 
refused 
x Fatal: Termination of life as an outcome of the AE. 
8.4. Reporting Procedures 
8.4.1. Serious Adverse Event Reporting 
When an Investigator determines that an AE meets the protocol definition of an SAE during the 
study, he/she must notify the Sponsor using an SAE Report Form within 24 hours of the study 
site personnel’s knowledge of the event , regardless of the Investigator assessment of the 
relationship of the event to study drug. Relevant information will be entered on the AE page and 
on all other applicable pages of the eCRF; source documentation should not be sent with the SAE Report Form unless requested. 
Follow-up information received on SAEs, should all be faxed to the Sponsor within 1 business 
day of receipt (refer to Medical Monitor/Sponsor Information page for contact [CONTACT_3031]). This 
information should be included on a follow-up SAE form and placed with the original SAE 
information. 
All SAEs will be followed until resolution, until the condition stabilizes, until the event is 
otherwise explained, or until the subject is lost to follow-up. 
The completed SAE Report Form should be submitted via email or fax to the SAE Reporting 
Contact [CONTACT_191850]/Sponsor Information Page  of this protocol. 
Do not delay reporting a suspected SAE in order to obtain additional information. Any additional information, if collected, can be reported as a follow-up to the initial report. 
8.4.2. Regulatory Reporting Requirements for Serious Adverse Events 
Prompt notification by [CONTACT_56481] e Sponsor of SAEs (even for noninterventional 
postmarketing studies) is essential so that legal obligations and ethical responsibilities towards 
the safety of subjects and the safety of a product under clinical investigation are met. DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-[ADDRESS_227932] under clinical investigation. The Sponsor will comply with country specific regulatory requirements relating to safety reporting to the regulatory authority, IRB/IEC, and Investigators. 
Investigator safety reports are prepared for su spected unexpected serious adverse reactions 
according to local regulatory requirements and are forwarded to Investigators as necessary. An Investigator who receives an Investigator safety  report describing a SAE(s) or other specific 
safety information (e.g., summary or listing of SAEs) from the Sponsor will file it with the 
Investigator’s Brochure and will notify the IRB/IEC, if appropriate, according to local requirements. 
8.5. Pregnancy Management and Reporting 
Any female subject who becomes pregnant during th e study will be withdrawn. Details will be 
collected for all pregnancies in female subjects and female partners of male subjects that begin 
after the start of dosing and through the Follow-up Visit. Pregnancy is not automatically considered an AE. 
If a pregnancy is reported, then the Investigator should complete a Pregnancy Report Form and 
submit via email or fax to the Pregnancy Reporting Contact [CONTACT_191851]/Sponsor Information Page of this protocol, within [ADDRESS_227933] will also be followed to determine the outcome of the 
pregnancy. Information on the status of the mother and child will be forwarded to the Sponsor. 
Generally, follow-up will be no longer than 6 to  8 weeks following the estimated delivery date. 
Any premature termination of the pregnancy will be reported. 
Any SAE occurring in association with a pregnancy brought to the Investigator’s attention after 
the subject has completed the study and considered by [CONTACT_191852]’s representative.  
The Investigator must attempt to collect pregnancy information on any female partners of male study subjects who become pregnant while the subject is enrolled in the study. Pregnancy information must be reported to the sponsor or the sponsor’s representative as described above. 
The partner will also be followed to determine the outcome of the pregnancy. Information on the status of the mother and child will be forwarded to Sponsor or the Sponsor’s representative. Generally, follow-up will be no longer than 6 to  8 weeks following the estimated delivery date. 
Any premature termination of the pregnancy will be reported on the pregnancy report form. 
8.6. Safety Oversight 
No independent Data Monitoring Committee will be used for this study; however, the Sponsor 
(including the Medical Monitor) will monitor safety on a periodic basis throughout the study DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-[ADDRESS_227934] current version of the 
Medical Dictionary for Regulatory Activities (MedDRA). Concomitant medications will be coded with the most current version of World Health Organization Drug Global Dictionary 
(WHODrugGlobal). 
The Investigator will retain original source documents and the Sponsor will receive 
eCRF-required data as electronic datasets. Subject init ials will not be collected or transmitted to 
the Sponsor. DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 54 10. STATISTICAL CONSIDERATIO NS AND DATA ANALYSES 
This study is intended to show that tapi[INVESTIGATOR_191809] a favorable safety and efficacy profile 
during repeated, intermittent treatment c ourses over an extended period of time. 
10.1. General Considerations 
All study data will be summarized overall by [CONTACT_191825][INVESTIGATOR_191810]. Categorical variables will be reported using frequency and percentage 
(e.g., gender, race). Continuous variables will be reported using number of subjects, mean, 
standard deviation (SD), median, minimum, and maximu m. All safety and efficacy data will be 
listed by [CONTACT_1130]. 
10.2. Determination of Sample Size 
The sample size of this study is based on the ICH E1 guideline on extent of population exposure to assess clinical safety for drugs intended for long-term treatment of non-life-threatening 
conditions. An estimated 850 subjects who complete Study DMVT-505-3001 or 
Study DMVT-505-3002 will be enrolled in this study across all regions. A high discontinuation rate is anticipated in this long-term extension study. Approximately 300 subjects are expected to 
complete the study (40 weeks of treatment). 
10.3. Analysis Populations 
All subjects enrolled into the study will be in cluded in the intent-to-tr eat (ITT) analysis set. 
10.4. Planned Analyses 
All efficacy and safety measures over the course of  the study will be presented. All analyses will 
be based on the ITT population. Details of planned analyses will be described in the Statistical Analysis Plan (SAP), which will be finalized prior to database lock. 
10.4.1. Demographics and Baseline Characteristics 
Demographics and baseline characteristics will be summarized and include frequency and 
percentages for categorical variables and mean, SD, median, minimum, and maximum for 
continuous variables. 10.4.2. Efficacy Analyses 
All efficacy analyses will be performed base d on the ITT analysis set as described above. 
Summaries will be presented by [CONTACT_191853][INVESTIGATOR_191811]. Summaries of efficacy endpoints by [CONTACT_191854] (OC) 
and last observation carried forward (LOCF) methods. 
Efficacy endpoints are as follows: 
x Proportion of subjects who experience a PGA ≥ [ADDRESS_227935] worsening (PGA ≥ 2) for subjects entering the 
study with a PGA score of clear (0) DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-[ADDRESS_227936]-reported DLQI total and 
individual dimension scores 
10.4.5. Analysis of Patient Satisfaction Questionnaire 
 
Responses for each question of the Patient Satisfaction Questionnaire will be summarized by [CONTACT_765]. 
10.5. Interim Analyses 
A data-cut will be made at the time of preparati on of the marketing appli cation to present interim 
results; the final analysis will be conducted  after study completion (e.g., the last subject ’s last 
visit). 
10.6. Handling of Missing Data 
Summaries of efficacy endpoints by [CONTACT_191854] (OC) and last 
observation carried forward (LOCF) methods. 
 DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 57 11. RESPONSIBILITIES 
11.1. Investigator Responsibilities 
11.1.1. Good Clinical Practice 
The Investigator will ensure that this study is conducted in accordance with the principles of the 
“Declaration of Helsinki” (as amended in Edinburgh, Tokyo, Venice, Hong Kong, and South 
Africa), ICH guidelines, or with the laws and regulations of the country in which the research is conducted, whichever affords the greater protecti on to the study subject. For studies conducted 
under a [LOCATION_002] (US) Investigational New Drug Application (IND), the Investigator will ensure that the basic princi ples of “Good Clinical Practice,” as outlined in 21  Code of Federal 
Regulations (CFR) 312, S ubpart D, “Responsibilities of Sponsors and Investigators,” 21 CFR, 
part 50, 1998, and 21 CFR, part 56, 1998, are adhered to. These standards are consistent with the requirements of the European Community Directive 2001/20/EC. 
Since this is a “covered” clinical trial, the Investigator will ensure that 21 CFR, Part 54, 1998, is 
adhered to; a “covered” clinical trial is any “study of a drug or device in humans submitte d in a 
marketing application or reclassi fication petition subject to this part that the applicant or Food 
and Drug Administration (FDA) relies on to establish that the product is effective (including studies that show equivalence to an effective produc t) or that make a significant contribution to 
the demonstration of safety. ” This requires that Investigators and all sub-investigators must 
provide documentation of their financial inter est or arrangements with the Sponsor, or 
proprietary interests in the drug being studied. This documentation must be provided before 
participation of the Investigator and any sub-investigator. The Investigator and sub-investigator 
agree to notify the Sponsor of any change reportable interests during the study and for [ADDRESS_227937]/Inde pendent Ethics Committee Approval 
This protocol and any accompanying material to be provided to the subject (such as 
advertisements, subject information sheets, or descriptions of the study used to obtain informed 
consent) will be submitted by [CONTACT_191855]. Approval from the IRB or IEC must be obtained before starting the study and should be documented in a letter to the 
Investigator specifying the protocol number, protocol version, protocol date, documents 
reviewed, and date on which the committee met and granted the approval. 
Any modifications made to the protocol after receipt of IRB or IEC approval must also be 
submitted to the IRB or IEC for approval before implementation. 
11.1.3. Informed Consent/Assent 
The Investigator is responsible for obtaining written informed consent/assent from each 
individual participating in this study after adequate explanation of the aims, methods, objectives, 
and potential hazards of the study and before undertaking any study-related procedures. The 
Investigator must utilize an IRB or IEC-approved consent form for documenting written DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-[ADDRESS_227938]’s legally authorized representative and the person obtaining consent.  
11.1.4. Confidentiality 
The Investigator must assure that subjects’ anonymity will be strictly m aintained and that their 
identities are protected from unauthorized parties. Only subject number, date of birth, and an 
identification code (e.g., not names) should be recorded on any form or biological sample submitted to the Sponsor, IRB or IEC, or laboratory. The Investigator must keep a screening log 
showing codes, names, and addresses for all Subjects screened and for all subjects enrolled in the 
trial. 
The Investigator agrees that all information receiv ed from the Sponsor, including but not limited 
to the Investigator’s Brochure, this protocol, eCRFs, the investigational new drug, and any other 
study information, remain the sole and exclusive property of the Sponsor during the conduct of 
the study and thereafter. This information is not to be disclosed to any third party (except 
employees or agents directly involved in the conduc t of the study or as required by [CONTACT_2371]) without 
prior written consent from the Sponsor. The Invest igator further agrees to take all reasonable 
precautions to prevent the disclosure by [CONTACT_191856]. 
11.1.5. Study Files and Retention of Records 
The Investigator must maintain adequate and ac curate records to enable the conduct of the study 
to be fully documented and the study data to be subsequently verified. These documents should 
be classified into at least the following 2 categories: (1) Investigator’s study file, and (2) subject 
clinical source documents. 
The Investigator’s study file will contain th e protocol/amendments, eCRF and query forms, IRB 
or IEC and governmental approval with correspondence, informed consent, drug records, staff 
curriculum vitae and authorization forms, and other appropriate documents and correspondence. 
The required source data should include the following for each subject: 
x Subject identification (name, date of birth, gender) 
x Documentation that subject meets eligibili ty criteria, e.g., history, physical 
examination, and confirmation of diagnosis (to support inclusion and exclusion criteria) 
x Participation in trial (including trial number) 
x Trial discussed and date of informed consent 
x Dates of all visits 
x Documentation that protocol specif ic procedures were performed 
x Results of efficacy parameters, as required by [CONTACT_760] 
x Start and end date (including dos e regimen) of trial medication  
(preferably drug dispensing and return should be documented as well) 
x Record of all adverse events and other safety parameters  (start and end date, and preferably including causality and intensity) DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 59 x Concomitant medication (including start a nd end date, dose if relevant; dose changes 
should be motivated) 
x Date of trial completion and reason for early discontinuation, if applicable 
All clinical study documents must be retained by [CONTACT_31201] [ADDRESS_227939] approval of a marketing application in an ICH region (e.g., US, Europe, or Japan) and until there are no pending or contemplated marketing applications in an ICH region; or, if no 
application is filed or if the application is not approved for such indication, until [ADDRESS_227940] been notified. Investigators may be 
required to retain documents longer if re quired by [CONTACT_25435] 
(e.g., 25 years in Canada), by [CONTACT_427], or by [CONTACT_16268]. The 
Investigator must notify the Sponsor before destroying any clinical study records. 
Should the Investigator wish to assign the study re cords to another party or move them to another 
location, the Sponsor must be notified in advance. 
If the Investigator cannot guarantee this archiving requirement at the study site for any or all the 
documents, special arrangements must be made between the Investigator and the Sponsor to 
store these in sealed containers outside of the si te so that they can be returned sealed to the 
Investigator in case of a regulatory audit. When source documents are required for the continued 
care of the subject, appropriate copi[INVESTIGATOR_69786]. 
Biological samples at the conclusion of this study may be retained in storage by [CONTACT_121190] 
a period up to [ADDRESS_227941] be completed and signed by [CONTACT_079] 
[INVESTIGATOR_11637]-investigator (as appropriate). This also applies to records for those Subjects who fail to 
complete the study. If a subject withdraws from the study, the reason must be noted on the eCRF. 
If a Subject is withdrawn from the study because of a treatment-limiting adverse event, thorough efforts should be made to clearly document the outcome. 
11.1.7. Drug Accountability 
The Investigator or designee (e.g., pharmacist) is responsible for ensuring adequate 
accountability of all used and unused investigational medicinal product, vehicles, and 
comparators. This includes acknowledgment of receipt of each shipment of study product 
(quantity and condition), subject dispensing records, and returned or destroyed study product. 
Dispensing records will document quantities received from the Sponsor and quantities dispensed 
to subjects, including lot number, date dispensed, subject identifier number, and the initials of the 
person dispensing the medication. 
At study initiation, the monitor will evaluate th e site’s procedure for investigational medicinal 
product disposal/destruction in order to ensure that it complies with the Sponsor requirements. 
At the end of the study, following final drug inventory reconciliation by [CONTACT_2037], the study site will dispose of and/or destroy all unused investigational medicinal product supplies, 
including empty containers, according to these procedures. If the site cann ot meet the Sponsor’s DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-[ADDRESS_227942] be obtained before changes can be implemented. 
11.2.2. Study Report and Publications 
A clinical study report will be prepared and provided to the regulatory agency(ies). The Sponsor 
will ensure that the report meets the standards set out in the ICH Guideline for Structure and 
Content of Clinical Study Reports (ICH E3). Note that an abbreviated report may be prepared in 
certain cases. 
After conclusion of the study and without pri or written approval from Dermavant Sciences 
GmbH, investigators in this study may communicate, orally present, or publish in scientific 
journals or other scholarly media only after the following conditions have been met: 
x The results of the study in their entirety have been publicly disclosed by [CONTACT_191857], in an abstract, manuscript, or presentation form 
OR 
x The study has been completed at all study sites for at least 5 years 
No such communication, presentation, or publication will include Dermavant Sciences GmbH, 
confidential information (see Section  11.1.4). 
The Investigator will submit any proposed publication or presentation along with the respective scientific journal or presentation forum at least [ADDRESS_227943] to delete 
references to its confidential information (other than the study results) in any paper or DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 61 presentation and agrees to withhold publication or presentation for an additional 60 days in order 
to obtain patent protection if deemed necessary. 
11.2.3. Posting of Information on Publicly Available Clinical Trial Registers 
Study information from this protocol will be poste d on publicly available clinical trial registers 
before enrollment of subjects begins. Re sults will be posted as required. 
11.3. Joint Investigator/Sponsor Responsibilities 
11.3.1. Access to Information for Monitoring 
In accordance with ICH Good Clinical Practice gui delines, the study monitor must have direct 
access to the Investigator’s source documentation in order to verify the data recorded in the 
CRFs for consistency. 
The monitor is responsible for routine review of the CRFs at regular intervals throughout the 
study to verify adherence to the protocol and th e completeness, consistency, and accuracy of the 
data being entered on them. The monitor should have access to any subject records needed to verify the entries on the CRFs. The Investigator agrees to cooperate with the monitor to ensure that any problems detected in the course of these monitoring visits are resolved. 
11.3.2. Access to Information for Auditing or Inspections 
To ensure compliance with Good Clinical Practices and all applicable regulatory requirements, 
Dermavant Sciences GmbH, may conduct a quality assurance audit. 
Authorized representatives of Dermavant Sciences GmbH, a regulatory authority, an IEC or 
an IRB may visit the site to perform audits or inspections, including source data verification. The 
purpose of a Dermavant Sciences GmbH, audit or inspection is to systematically and 
independently examine all study-related activities and documents to determine whether these activities were conducted, and da ta were recorded, analyzed, a nd accurately reported according 
to the protocol, Good Clinical Practice guidelines of the ICH, and any applicable regulatory 
requirements. The Investigator should contact [CONTACT_191858] a regulatory agency about an  inspection. 
Representatives of regulatory authorities or of the Sponsor may conduct inspections or audits of the clinical study. If the Investigator is notified of an inspection by a regulatory authority the 
Investigator agrees to notify the Sponsor Medical Monitor immediately. The Investigator agrees 
to provide to representatives of a regulatory agency or the Sponsor access to records, facilities, 
and personnel for the effective conduct of any inspection or audit. 
11.3.3. Study Discontinuation 
The Sponsor reserves the right to terminate the stud y at any time. Should this be necessary, the 
Sponsor will arrange discontinuation procedures and notify the appropriate regulatory 
authority(ies), IRBs, and IECs. In terminating the study, the Sponsor and the Investigator will assure that adequate cons ideration is given to the protection of the s ubjects’ interests.  DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 62 12. REFERENCES 
Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AY Dermatology. Determining the 
minimal clinically important difference and res ponsiveness of the Dermatology Life Quality 
Index (DLQI): further data.2015;230(1):27-33. 
Cappon GD and Hurtt ME. Developmental toxicity of the kidney. In: Kapp RW and Yyl L, 
editors. Reproductive Toxicology, Target Organ Series, 3rd edition. [LOCATION_001]:Informa Healthcare, 2010:193-204. 
Frazier KS and Seely JC. Urinary system. In: Sahota PS, Popp JA, Hardisty JF and Gopi[INVESTIGATOR_92063] C, 
editors. Toxicologic Pathology: Nonclinical Safety Assessment. CRC Press, 2013:421-84. 
International Conference on Harmonisation, Guideline for the extent of population exposure to 
assess clinical safety for drugs intended for long-term treatment of non-life-threatening 
conditions. 1994. Available at: https://www.ic h.org/fileadmin/Public_Web_Site/ICH_Products/ 
Guidelines/Efficacy/E1/Step4/E1_Guideline.pdf.  
Mason AR, Mason J, Cork M, Dooley G, Hancock H. Topi[INVESTIGATOR_191812]. Cochrane Database of Systematic Reviews. 2013;(3):CD005028. doi: 10.1002/14651858.CD005028.pub3. 
Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epi[INVESTIGATOR_82701]: a 
systematic review of incidence and prev alence. J Invest Dermatol. 2012;133:377-385. 
Zoetis T and Hurtt ME. Species comparison of anatomical and functional renal development. Birth Defects Research Part B. 2003;68:111-120. DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003
Dermavant Sciences GmbH Clinical Study Protocol 
Confidential Page 6313. APPENDICES
PHYSICIAN GLOBAL ASSESSMENT
Each assessment should be made as a visual ‘avera ge’ of the severity of all treated areas at the 
time of the assessment. Following the Baseline visi t, assessments will be made without reference 
to Baseline state or any other previous scores.
Scoring should not be influenced by [CONTACT_191859], subject symptoms, or impact on subject ’s 
quality of life.
Score/Grade Description
0 Clear No signs of psoriasis; postinflammatory hyperpi[INVESTIGATOR_22765]
1Almost 
clearNo thickening; normal to pi[INVESTIGATOR_191813]; no to minimal focal scaling
[ADDRESS_227944] detectable to mild thickening; pi[INVESTIGATOR_191814]; predominantly fine 
scaling
3 ModerateClearly distinguishable to moderate thickening;  dull to bright red, clearly distinguishable 
erythema; moderate scaling
[ADDRESS_227945] edges; bright to  deep dark red coloration; severe/coarse 
scaling covering almost all or all lesions
Langley RGB, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C. The 5- point Investigator’s Global Assessment (IGA) 
Scale: A modified tool for evaluating plaque psoriasis severi ty in clinical trials. J Dermatolog Treat. 2015;26(1):23-31.DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003
Dermavant Sciences GmbH Clinical Study Protocol 
Confidential Page 66
DERMATOLOGY LIFE QUALIT Y INDEX (DLQI) AGES 
[ADDRESS_227946] week, how itchy , sore , painful or stinging has your skin been? Very much
A lot
A little
Not at all
2.Over the last week, how embarrassed or self conscious have you been 
because of your skin?Very much
A lot
A little
Not at all
3.Over the last week, how much has your skin interfered with you going 
shoppi[INVESTIGATOR_191815]?Very much
A lot
A little
Not at all
    Not relevant
4.Over the last week, how much has your skin influenced the clothes you 
wear?Very much
A lot
A little
Not at all
    Not relevant
5.Over the last week, how much has your skin affected any social or leisure
activities?Very much
A lot
A little
Not at all
    Not relevant
6.Over the last week, how much has your skin made it difficult for you to do 
any sport ?Very much
A lot
A little
Not at all
    Not relevant
7.Over the last week, has your skin prevented you from working or studying ? Yes
No
    Not relevant
If "No", over the last week how much has your skin been a problem at work
or studying ?A lot
A little
Not at all 
8.Over the last week, how much has your skin created problems with your 
partner or any of your close friends or relatives? Very much
A lot
A little
Not at all
    Not relevant
9.Over the last week, how much has your skin caused any sexual difficulties? Very much
A lot
A little
Not at all
    Not relevant
10.Over the last week, how much of a problem has the treatment for your skin 
been, for example by [CONTACT_80243], or by [CONTACT_78469]?Very much
A lot
A little
Not at all
    Not relevant
© AY Finlay, GK Khan, April [ADDRESS_227947] not be copi[INVESTIGATOR_191816].DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003
Dermavant Sciences GmbH Clinical Study Protocol 
Confidential Page 67
LOCAL TOLERABILITY SCALE ASSESSMENT
At each specified study visit, the investigator (or qualified evaluator) will assess the presence and 
overall degree of irritation at the application sites, according to the 5-point scale. The score will 
ideally represent an ‘average’ across all applicat ion sites. To the fullest extent possible, the same 
investigator (or designated evaluator) will perform all tolerability assessments for an individual subject throughout the study.
If the subject is applying study treatment to “sensitive areas” ( e.g.,genitals, face, neck, and skin folds), 
then also assess the degree of irritation for these areas.
Local Tolerability –Dryness, Erythema, and Peeling
Score Severity Description
0 No irritation No evidence of loca l irritation/intolerance
1 Mild Minimal erythema and/or edem a, slight glazed appearance
2 Moderate Definite erythema and/or edema with peeling and/or cracking but does not require 
treatment modification
[ADDRESS_227948] will use a 5-point tolerability scale to assess the 
presence and degree of burning/stinging and itching at the treatment areas. The score will ideally represent an ‘average’ across all application sites.
Local Tolerability –Burning/Stinging and Itching
Score Severity Description
0 None Normal, no discomfort
1 Slight An awareness, but no discomfort and no intervention required
2 Mild A noticeable discomfort that causes intermittent awareness
3 Moderate A noticeable discomfort that causes intermittent awareness and interferes occasionally
with normal daily activities
4 Strong/Severe A definite continuous discomfort that interferes with normal daily activitiesDocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003
Dermavant Sciences GmbH Clinical Study Protocol 
Confidential Page 68
PATIENT SATISFACTION QUESTIONNAIRE
You are being asked the below questions to better understand how you feel about the cream 
medication (study drug) you used to treat your psoriasis in this study and how it compares to other medications you have used to treat your psoriasis in the past.  When answering each question, think about the cream medication (study dr ug) that you have been using as a patient in 
this study.  Please circle the answer that most closely matches how you feel.  
1. I can easily manage my psoriasis with the study drug 
Strongly Agree Agree Neutral Disagree Strongly Disagree
2. The time spent applying the study drug every day was acceptable and did not affect my 
everyday life 
Strongly Agree Agree Neutral Disagree Strongly Disagree
3. I am satisfied with how well the study drug worked for my psoriasis
Strongly Agree Agree Neutral Disagree Strongly Disagree
4. I have confidence in the study drug 
Strongly Agree Agree Neutral Disagree Strongly Disagree
5. The study drug cleared my skin and kept my psoriasis from coming back 
Strongly Agree Agree Neutral Disagree Strongly Disagree
6. If the study drug was available by [CONTACT_50246], I would recommend it to other patients with 
psoriasisStrongly Agree Agree Neutral Disagree Strongly Disagree
7. If the study drug was available by a prescription, I would use it again or continue on it
Strongly Agree Agree Neutral Disagree Strongly Disagree
8. The study drug is easy to apply
Strongly Agree Agree Neutral Disagree Strongly Disagree
9. The study drug is not greasy 
Strongly Agree Agree Neutral Disagree Strongly Disagree
10. The study drug quickly absorbs into my skin 
Strongly Agree Agree Neutral Disagree Strongly Disagree
11. The study drug feels good on my skin 
Strongly Agree Agree Neutral Disagree Strongly Disagree
12. I am satisfied with the look and feel of the study drug 
Strongly Agree Agree Neutral Disagree Strongly DisagreeDocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 69 The below questions # 13-[ADDRESS_227949]?  Yes/no.  If yes, please answer 
questions 13-15.  If no, please go to question 16.   
13. The study drug is more effective than other topi[INVESTIGATOR_191817] I have used to treat my psoriasis  
Strongly Agree  Agree  Neutral  Disagree  Strongly Disagree 
 
14. The study drug is easier to use than other topi[INVESTIGATOR_191817] I have used to treat my psoriasis 
Strongly Agree  Agree  Neutral  Disagree  Strongly Disagree 
 
15. I prefer the study drug to other topi[INVESTIGATOR_191817] I have used to treat my psoriasis   
Strongly Agree  Agree  Neutral  Disagree  Strongly Disagree 
 
Have you used systemic drugs to treat your psoriasis in the past?  Yes/no.  If yes, please answer the 
following questions.  If no, that is the end of the questionnaire.   
16. The study drug is more effective than systemic drugs I have used to treat my psoriasis 
Strongly Agree  Agree  Neutral  Disagree  Strongly Disagree 
 
17. The study drug is easier to use than systemic drugs I have used to treat my psoriasis  
Strongly Agree  Agree  Neutral  Disagree  Strongly Disagree 
 
18. I prefer the study drug to systemic drugs I have used to treat my psoriasis 
Strongly Agree  Agree  Neutral  Disagree  Strongly Disagree 
 
Thank you very much for your participation in this clinical study and questionnaire.   DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003
Dermavant Sciences GmbH Clinical Study Protocol 
Confidential Page 70
PROTOCOL AMENDMENT SUMMARY OF CHANGES
The protocol has been updated with the following changes.  Edits to the protocol are shown in 
bold .
ABBREVIATIONS
Added LOCF (Last Observation Carried Forward). Added OC (Observed Cases); Updated 
WHODrugGlobal to WHO (World Health Organization)
SYNOPSIS
Added statement on use of rescue medication.Inclusion criteria: revised contraception language for clarity.
The following efficacy study endpoints were added : 
xProportion of subjects who experience a PGA ≥ [ADDRESS_227950] worsening (PGA ≥ 2) for subjects entering the study 
with a PGA score of clear (0)
xProportion of subjects who achieve a PGA score of [ADDRESS_227951] achieving a PGA score of 0 for subjects entering the study with a PGA score ≥ 1
xDuration of each treatment epi[INVESTIGATOR_1865], defined as time from each treatment initiation/re-
initiation to each subsequent treatment success (PGA score of 0).
xDuration of each treatment succ ess (PGA score of 0) to each subsequent worsening (PGA 
≥ 2)
xProportion of subjects who never achieve a PGA ≥ 2 throughout the study
xProportion of subjects who never achieve a PGA score of 0 or 1 throughout the study
xProportion of subjects who never achieve a PGA score of 0 throughout the study
xPGA scores by [CONTACT_765] (OC and LOCF)
xChange and percent change from baseline in %BSA affected by [CONTACT_765] (OC and LOCF)
xChange and percent change in PASI score by [CONTACT_765] (OC and LOCF)
The following study endpoints were deleted : 
xMedian time from each treatment success (PGA 0 or 1) to each subsequent worsening (PGA ≥ 2)
xProportion of subjects who have a PGA score of clear (0) after treatment
xProportion of subjects who have a PGA score of clear (0) or almost clear (1) after 
treatment
xProportion of subjects who do not experience disease worsening (PGA ≥ 2)
xChange over time in percent of %BSA affected
xMean duration of each treatment course
xPercent change over time in PASI score
The statistical method section was upda ted for clarification as follows: DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 71 All study data will be summarized overall and  by [CONTACT_191825][INVESTIGATOR_191818]-to-treat (ITT) analysis set of subjects.   
The Kaplan-Meier product limit method will be used  to estimate the median time (if estimable) 
from baseline to first disease worsening and first disease success  (PGA≥2).   
 Duplicative section of Dura tion of Treatment was deleted
 
Table 1. Schedule of Assessment 
Addition of clinical photography, as applicable at Visits 1-11. Removal of diary and study drug assessments for phone call check at Week 2.  Rem oval of study drug application at the last visit 
(Week 40). Correction of footnote on disease worsening. LTS assessments completed by [CONTACT_191860] (Visit 1). Footnote i. was updated 
to include: This assessment is only required to be  completed if the subject was applying study 
drug. Update to footnotes g-m to accommodate phot ography addition. Added Patient Satisfaction 
Questionnaire at Visit 11. 
Section 1.[ADDRESS_227952] language in study report; “contact [CONTACT_8748]” changed to “dermatitis 
contact.”  
The most frequently reported (1% to 6% of 235 subjects) dermatological adverse events (AEs), regardless of causality, were application site discoloration/hyperpi[INVESTIGATOR_371], application site 
dermatitis, papular rash, prur itus, contact [CONTACT_191861], folliculitis, erythema, and skin 
burning sensation.   
Section [IP_ADDRESS]. Clarification on study design added; 
In the open-label PK  Study 201851 with BID dosing  of Formulation F of tapi[INVESTIGATOR_191753] 
(n=11) , 1% and 2%, headache was the most frequently reported during the study (reported for 
100% and 60% of subjects at the 1% and 2% doses, respectively). 
Corrected typographical error: To mitigate potential systemic risks, subjects will be monitored 
for AEs and any abnormal vital signs, physical examination, and laboratory test results.  Section 2. Objectives and Endpoints 
The following safety and tolerability endpoint wa s added to this section for consistency with 
other sections within this protocol: Mean scores by [CONTACT_191862] : 
x Proportion of subjects who experience a PGA ≥ [ADDRESS_227953] worsening (PGA ≥ 2) for subjects entering the study 
with a PGA score of clear (0) 
x Proportion of subjects who achieve a PGA score of [ADDRESS_227954] achieving a PGA score of 0 for subjects entering the 
study with a PGA score ≥ 1 
x Duration of each treatment epi[INVESTIGATOR_1865], defined as time from each treatment initiation/re-
initiation to each subsequent treatment success (PGA score of 0). DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 72 x Duration of each treatment succ ess (PGA score of 0) to each  subsequent worsening (PGA 
≥ 2) 
x Proportion of subjects who never achieve a PGA ≥ 2 throughout the study 
x Proportion of subjects who never achieve a PGA score of 0 or 1 throughout the study 
x Proportion of subjects who never achieve a PGA score of 0 throughout the study 
x PGA scores by [CONTACT_765] (OC and LOCF) 
x Change and percent change from baseline in %BSA affected by [CONTACT_765] (OC and LOCF) 
x Change and percent change in PASI score by [CONTACT_765] (OC and LOCF) 
x Change in disease impact on daily activities, as measured by [CONTACT_191863] :  
• Median time from each treatment success (PGA 0 or 1) to each subsequent worsening 
(PGA ≥ 2) 
• Proportion of subjects who have a PGA score of clear (0) after treatment 
• Proportion of subjects who have a PGA score of clear (0) or almost clear (1) after 
treatment 
• Proportion of subjects who do not experience disease worsening (PGA ≥ 2) 
• Change over time in percent of %BSA affected • Mean duration of each treatment course 
• Percent change over time in PASI score 
Section 3.1 Overall Design 
Clarified wording around time of dosing each da y and protocol violations which is further 
addressed in Section 5.1.5 (Administration of Study Drug) Added statement on use of rescue medication. 
Section 4.2 Inclusion Criteria 
Revised contraception la nguage for clarity. 
Section 5.1.5.  Administration of Study Drug 
Provided clarification on applicati on to affected areas for those entering with a PGA score of 0 or 
> 0. 
Added clarification wording around mi ssed doses and protocol deviations: “ If a subject misses a 
daily dose, it will be recorded as a protocol deviation. The subject should continue dosing 
the next day and should not apply more than on ce daily to make up for the missed dose on 
the previous day. ” 
Section 5.4 
Clarified that unopened tubes may only be dispensed one time. 
Section 5.6 Prior and Concomitant Therapy DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 73 Removed wording on collection of concomitant medica tion for 30 days prior to the baseline visit 
as these medications will already being collec ted as part of the prior pi[INVESTIGATOR_2397]. 
Section [IP_ADDRESS]. Physician Global Assessment 
Corrected typographical error: higher PGA scores represent more sever e disease.  
Section [IP_ADDRESS] patient Satisfaction Questionnaire 
Added that subjects will complete the Patient Satisfaction Questionnaire and referenced 
Appendix 5. 
Section 6.2.3. Optional Clinical Photography 
Clinical photography may be performed in a subgroup of subjects at selected study centers that 
participated in photography in the pi[INVESTIGATOR_2397]. This is not required of subjects for participation 
in the study. Informed consent and photographic release will be required. The photographs may not be referred to by [CONTACT_191864]. 
Photographs will be taken of a representative area  of the subject’s disease area at the time points 
specified in the Schedule of Assessments (Table 1; see also section 7). Three photographs of the 
selected skin area will be taken in a standardi zed fashion (ie, same camera, angle, background, 
distance). Procedures for the clinical photography w ill be contained in the Photography Manual. 
Section 6.3.5 Local Tolerability Scale 
Clarified that the LTS will only be completed by [CONTACT_191865]. 
Section 7.1 Visit 1; Baseline 
Added photography of a representative area of the subject’s disease area (optional; at a 
subsection of study centers) (last assessment from pi[INVESTIGATOR_2397]) 
Removed LTS (last assessment from parent study) 
Section 7.2 Visits 2 to 101; Treatment Period  
The title of the section was updated to accuratel y reflect the visits. Added Photography of a 
representative area of the subject’s disease area (optio nal; at a subsection of study centers)   
Section 7.[ADDRESS_227955] at Week 2 (Day 15±3 Days) 
The title of this section was renumbered to Section 7.[ADDRESS_227956]’s disease area (optional; at a subsection of study centers). Correction made to 
remove the requirement for a study visit. “If disease worsening is confirmed, a new treatment 
course will be initiated, and the subject will be  scheduled to return to the study site after 2 
weeks .” 
Section 7.6 Early Termination  DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4
Tapi[INVESTIGATOR_191750]-505-3003 
Dermavant Sciences GmbH Clinical Study Protocol  
 
Confidential Page 74 The title of this section was renumbered to  Section 7.7. Added the Patient Satisfaction 
Questionnaire.  
Section 7.7 End of Study  
The title of this section was renumbered to Section 7.8.  
Section 8.1.1. Definition of Adverse Events 
To avoid confusion, the wording that defines local adverse events has been edited since 
“evaluation of local tolerability” is being assessed with a specific scale (Appendix 8).  
Section 8.1.3. Adverse Events of Special Interest 
Changed wording to state that “ study drug will may be discontinued, and study drug may be 
restarted when event resolves ”, if a subject has an adverse event of special interest  
Section 8.2.2 Assigning Causal Relationship to Study Drug 
Updated to allow Principal Investigator [INVESTIGATOR_191819]-Investigators. 
Changed wording to state that “ Causality assessment may only be delegated to a Principal 
Investigator [INVESTIGATOR_54720]-Investigator; ” 
Section 10.4.2. Efficacy Analyses 
Updated with revised efficacy endpoints described in the synopsis and Section 2. 
Section 10.4.5. Analysis of Patient Satisfaction Questionnaire 
Statistical analysis of the Patient Sa tisfaction Questionnaire was added. 
Section 10.6 Handling of Missing Data 
Section updated as follows: Missing data will not be imputed. Summaries of efficacy endpoints 
by [CONTACT_191866] (OC) and last observation carried forward 
(LOCF) methods . 
Appendix 3, page 75. CALCULATION of BSA and PASI 
Clarification of body surface area calculation a nd correction in table for calculation of PASI; 
score of 0 changed from 1% to 0% skin covered with psoriasis and score of 1 changed from 1 - 
<10% to <10% consistent with published paper (Feldman Feldma n SR, Krueger GG. Psoriasis 
assessment tools in clinical trials. Ann Rheum Dis.2005;64 (suppl II):ii65-ii68.) 
 Percentage of skin covered with psoriasis for each of the 4 areas 
Affected  0% < 10% 10 - < 30% 30 - < 50% 50 - < 70% 70 - < 90% ≥ 90% 
Score 0 1 2 3 4 5 6 
In addition, the Area Score has been shaded and will be auto-calculated in the eCRF. 
Appendix 5. Patient Satisfaction Questionnaire  
New appendix added with example questions. DocuSign Envelope ID: A86CDA99-5519-45D7-AB4A-2A81BB86EDE4